<!DOCTYPE html>
<html><head><meta charset="UTF-8">
<title>Earnings Call ë²ˆì—­</title>
<style>
    body { font-family: Arial; margin: 40px; background-color: #fdfdfd; }
    h1 { text-align: center; }
    h2 { margin-top: 50px; color: #003366; }
    h3 { color: #333; }
    table { border: 1px solid #ddd; width: 100%; border-collapse: collapse; }
    th { background: #f0f0f0; padding: 10px; border-bottom: 2px solid #ccc; }
    td { padding: 10px; border-bottom: 1px dotted #ccc; vertical-align: top; }
    p { line-height: 1.6; }
    hr { margin: 50px 0; border: none; border-top: 1px solid #ccc; }
    .back-button {
        display: inline-block;
        background-color: #5f5f5f;
        color: white;
        padding: 10px 16px;
        border-radius: 6px;
        text-decoration: none;
        font-weight: 500;
        box-shadow: 0 2px 6px rgba(0,0,0,0.1);
        margin-bottom: 30px;
    }
</style>
</head><body>
<a href="../../index.html" class="back-button">â†</a>
<h1>ğŸ“„ Earnings Call Transcript ë²ˆì—­ ê²°ê³¼</h1>

    <h2>ğŸ“Š Presentation</h2>
    <table style="width:100%; border-collapse:collapse; margin-bottom: 40px;">
        <tr>
            <th style="width:50%; border-bottom: 2px solid #333;">Original</th>
            <th style="width:50%; border-bottom: 2px solid #333;">Translation</th>
        </tr>
        <tr><td>Oddity Tech Ltd. (NASDAQ:ODD) Q2 2025 Earnings Conference Call August 5, 2025 8:30 AM ET<br><br>Company Participants<br><br>Lindsay Drucker Mann - Global Chief Financial Officer<br>Maria Lycouris - Corporate Participant<br>Oran Holtzman - Co-Founder, CEO & Director<br><br>Conference Call Participants<br><br>Andrew M. Boone - Citizens JMP Securities, LLC, Research Division<br>Anna Jeanne Lizzul - BofA Securities, Research Division<br>Dara Warren Mohsenian - Morgan Stanley, Research Division<br>Lauren Rae Lieberman - Barclays Bank PLC, Research Division<br>Mark Stephen F.</td><td>Oddity Tech Ltd. (NASDAQ:ODD) 2025ë…„ 2ë¶„ê¸° ì‹¤ì  ì»¨í¼ëŸ°ìŠ¤ ì½œ 2025ë…„ 8ì›” 5ì¼ ì˜¤ì „ 8ì‹œ 30ë¶„ ET<br><br>íšŒì‚¬ ì°¸ì„ì<br><br>Lindsay Drucker Mann - ê¸€ë¡œë²Œ ìµœê³ ì¬ë¬´ì±…ì„ì<br>Maria Lycouris - ê¸°ì—… ì°¸ì„ì  <br>Oran Holtzman - ê³µë™ì°½ë¦½ì, CEO ê²¸ ì´ì‚¬<br><br>ì»¨í¼ëŸ°ìŠ¤ ì½œ ì°¸ì„ì<br><br>Andrew M. Boone - Citizens JMP Securities, LLC, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>Anna Jeanne Lizzul - BofA Securities, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>Dara Warren Mohsenian - Morgan Stanley, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>Lauren Rae Lieberman - Barclays Bank PLC, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>Mark Stephen F.</td></tr>
<tr><td>Mahaney - Evercore ISI Institutional Equities, Research Division<br>Scott Anthony Schoenhaus - KeyBanc Capital Markets Inc., Research Division<br>Youssef Houssaini Squali - Truist Securities, Inc., Research Division<br><br>Operator<br><br>Good morning, and welcome to ODDITY's Second Quarter 2025 Earnings Conference Call. Today's call is being recorded, and we have allocated time for prepared remarks and Q&A. At this time, I'd like to turn the conference over to Maria Lycouris, Investor Relations for ODDITY. Thank you. You may begin. Maria Lycouris<br><br>Thank you, operator. I'm joined by Oran Holtzman, ODDITY's Co-Founder and CEO; and Lindsay Drucker Mann, ODDITY's Global CFO.</td><td>ë§ˆí•˜ë‹ˆ - ì—ë²„ì½”ì–´ ISI ê¸°ê´€íˆ¬ìì ì£¼ì‹ë¶€, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>ìŠ¤ì½§ ì•¤ì„œë‹ˆ ì‡¤í•˜ìš°ìŠ¤ - í‚¤ë±…í¬ ìºí”¼í„¸ ë§ˆì¼“ì¸ , ë¦¬ì„œì¹˜ ë¶€ë¬¸  <br>ìœ ì„¸í”„ í›„ì‚¬ì´ë‹ˆ ìŠ¤ì½¸ë¦¬ - íŠ¸ë£¨ì´ìŠ¤íŠ¸ ì‹œíë¦¬í‹°ì¦ˆ, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br><br>ì˜¤í¼ë ˆì´í„°<br><br>ì•ˆë…•í•˜ì„¸ìš”. ODDITYì˜ 2025ë…„ 2ë¶„ê¸° ì‹¤ì  ì»¨í¼ëŸ°ìŠ¤ ì½œì— ì˜¤ì‹  ê²ƒì„ í™˜ì˜í•©ë‹ˆë‹¤. ì˜¤ëŠ˜ í†µí™”ëŠ” ë…¹ìŒë˜ê³  ìˆìœ¼ë©°, ë°œí‘œì™€ ì§ˆì˜ì‘ë‹µ ì‹œê°„ì„ í• ë‹¹í–ˆìŠµë‹ˆë‹¤. ì´ì œ ODDITYì˜ íˆ¬ìì ê´€ê³„ ë‹´ë‹¹ ë§ˆë¦¬ì•„ ë¦¬ì¿ ë¦¬ìŠ¤ì—ê²Œ íšŒì˜ë¥¼ ë„˜ê¸°ê² ìŠµë‹ˆë‹¤. ê°ì‚¬í•©ë‹ˆë‹¤. ì‹œì‘í•˜ì‹œê¸° ë°”ëë‹ˆë‹¤.<br><br>ë§ˆë¦¬ì•„ ë¦¬ì¿ ë¦¬ìŠ¤<br><br>ê°ì‚¬í•©ë‹ˆë‹¤, ì˜¤í¼ë ˆì´í„°. ODDITYì˜ ê³µë™ì°½ë¦½ì ê²¸ CEOì¸ ì˜¤ë€ í™€ì¸ ë§Œê³¼ ODDITYì˜ ê¸€ë¡œë²Œ CFOì¸ ë¦°ì§€ ë“œëŸ¬ì»¤ ë§Œì´ í•¨ê»˜ ì°¸ì„í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Niv Price, ODDITY's CTO, will also be available for the question-and-answer session. As a reminder, management's remarks on this call that do not concern past events or forward-looking statements. These may include predictions, expectations or estimates, including statements about ODDITY's business strategy, market opportunity, future financial performance and potential long-term success. Forward-looking statements involve risks and uncertainties, and actual results could differ materially due to a variety of factors.</td><td>ODDITYì˜ CTOì¸ ë‹ˆë¸Œ í”„ë¼ì´ìŠ¤(Niv Price)ë„ ì§ˆì˜ì‘ë‹µ ì„¸ì…˜ì— ì°¸ì„í•  ì˜ˆì •ì…ë‹ˆë‹¤. ë§ì”€ë“œë¦¬ìë©´, ì´ë²ˆ ì»¨í¼ëŸ°ìŠ¤ ì½œì—ì„œ ê²½ì˜ì§„ì˜ ë°œì–¸ ì¤‘ ê³¼ê±° ì‚¬ê±´ì— ê´€í•œ ê²ƒì´ ì•„ë‹Œ ë‚´ìš©ë“¤ì€ ë¯¸ë˜ì „ë§ì§„ìˆ ì— í•´ë‹¹í•©ë‹ˆë‹¤. ì—¬ê¸°ì—ëŠ” ODDITYì˜ ì‚¬ì—… ì „ëµ, ì‹œì¥ ê¸°íšŒ, í–¥í›„ ì¬ë¬´ ì„±ê³¼ ë° ì ì¬ì  ì¥ê¸° ì„±ê³µì— ëŒ€í•œ ì˜ˆì¸¡, ê¸°ëŒ€ì¹˜ ë˜ëŠ” ì¶”ì •ì¹˜ë¥¼ í¬í•¨í•œ ì§„ìˆ ë“¤ì´ í¬í•¨ë©ë‹ˆë‹¤. ë¯¸ë˜ì „ë§ì§„ìˆ ì€ ë¦¬ìŠ¤í¬ì™€ ë¶ˆí™•ì‹¤ì„±ì„ ìˆ˜ë°˜í•˜ë©°, ë‹¤ì–‘í•œ ìš”ì¸ë“¤ë¡œ ì¸í•´ ì‹¤ì œ ê²°ê³¼ëŠ” í¬ê²Œ ë‹¬ë¼ì§ˆ ìˆ˜ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>These factors are described under forward-looking statements in our earnings press release issued yesterday and in our most recent annual report on Form 20-F filed with the Securities and Exchange Commission on February 25, 2025. We do not undertake any obligation to update forward-looking statements, which speak only as of today. Finally, during this call, we will discuss certain non-GAAP financial measures, which we believe are useful supplemental measures for understanding our business. Additional information about these non-GAAP financial measures, including their definitions are included in our earnings press release, which we issued yesterday. I'll now hand the call over to Oran.</td><td>ì´ëŸ¬í•œ ìš”ì¸ë“¤ì€ ì–´ì œ ë°œí‘œëœ ì‹¤ì  ë³´ë„ìë£Œì˜ ë¯¸ë˜ì˜ˆì¸¡ì§„ìˆ  ë¶€ë¶„ê³¼ 2025ë…„ 2ì›” 25ì¼ ì¦ê¶Œê±°ë˜ìœ„ì›íšŒì— ì œì¶œëœ ë‹¹ì‚¬ì˜ ìµœì‹  Form 20-F ì—°ì°¨ë³´ê³ ì„œì— ê¸°ìˆ ë˜ì–´ ìˆìŠµë‹ˆë‹¤. ë‹¹ì‚¬ëŠ” ì˜¤ëŠ˜ í˜„ì¬ë¥¼ ê¸°ì¤€ìœ¼ë¡œë§Œ ìœ íš¨í•œ ë¯¸ë˜ì˜ˆì¸¡ì§„ìˆ ì„ ì—…ë°ì´íŠ¸í•  ì˜ë¬´ë¥¼ ì§€ì§€ ì•ŠìŠµë‹ˆë‹¤. ë§ˆì§€ë§‰ìœ¼ë¡œ, ì´ë²ˆ ì»¨í¼ëŸ°ìŠ¤ ì½œì—ì„œëŠ” ë‹¹ì‚¬ ì‚¬ì—…ì„ ì´í•´í•˜ëŠ” ë° ìœ ìš©í•œ ë³´ì™„ì  ì§€í‘œë¼ê³  íŒë‹¨ë˜ëŠ” íŠ¹ì • ë¹„GAAP ì¬ë¬´ì§€í‘œë“¤ì— ëŒ€í•´ ë…¼ì˜í•  ì˜ˆì •ì…ë‹ˆë‹¤. ì´ëŸ¬í•œ ë¹„GAAP ì¬ë¬´ì§€í‘œë“¤ì— ëŒ€í•œ ì¶”ê°€ ì •ë³´ì™€ ì •ì˜ëŠ” ì–´ì œ ë°œí‘œí•œ ì‹¤ì  ë³´ë„ìë£Œì— í¬í•¨ë˜ì–´ ìˆìŠµë‹ˆë‹¤. ì´ì œ ì˜¤ë€ì—ê²Œ ë§ˆì´í¬ë¥¼ ë„˜ê¸°ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Oran Holtzman<br><br>Thanks, everyone, for joining us today. ODDITY's momentum in 2025 continues with another strong result this quarter and great progress on our long-term growth initiatives. Our financial performance year-to-date is another proof point of our success. For the first half of 2025, we grew revenue 26% to $509 million, generated adjusted EBITDA of $122 million and free cash flow of $99 million. This is more EBITDA and more free cash flow in the first half of the year than we delivered for the entire full year of 2023, the year of our IPO.</td><td>ì˜¤ë€ í™€ì¸ ë§Œ<br><br>ì˜¤ëŠ˜ ì €í¬ì™€ í•¨ê»˜í•´ ì£¼ì‹  ëª¨ë“  ë¶„ë“¤ê»˜ ê°ì‚¬ë“œë¦½ë‹ˆë‹¤. ODDITYì˜ 2025ë…„ ëª¨ë©˜í…€ì€ ì´ë²ˆ ë¶„ê¸° ë˜ ë‹¤ë¥¸ ê°•ë ¥í•œ ì‹¤ì ê³¼ ì¥ê¸° ì„±ì¥ ì´ë‹ˆì…”í‹°ë¸Œì—ì„œì˜ í›Œë¥­í•œ ì§„ì „ê³¼ í•¨ê»˜ ê³„ì†ë˜ê³  ìˆìŠµë‹ˆë‹¤. ì—°ì´ˆ ëŒ€ë¹„ ì €í¬ì˜ ì¬ë¬´ ì„±ê³¼ëŠ” ì €í¬ ì„±ê³µì˜ ë˜ ë‹¤ë¥¸ ì¦ê±°ì…ë‹ˆë‹¤. 2025ë…„ ìƒë°˜ê¸° ë™ì•ˆ ë§¤ì¶œì€ 26% ì¦ê°€í•œ 5ì–µ 900ë§Œ ë‹¬ëŸ¬ë¥¼ ê¸°ë¡í–ˆìœ¼ë©°, ì¡°ì • EBITDA 1ì–µ 2,200ë§Œ ë‹¬ëŸ¬ì™€ ì‰ì—¬í˜„ê¸ˆíë¦„ 9,900ë§Œ ë‹¬ëŸ¬ë¥¼ ì°½ì¶œí–ˆìŠµë‹ˆë‹¤. ì´ëŠ” ì €í¬ IPO ì—°ë„ì¸ 2023ë…„ ì „ì²´ ì—°ë„ì— ë‹¬ì„±í–ˆë˜ ê²ƒë³´ë‹¤ ìƒë°˜ê¸°ì—ë§Œ ë” ë§ì€ EBITDAì™€ ë” ë§ì€ ì‰ì—¬í˜„ê¸ˆíë¦„ì„ ê¸°ë¡í•œ ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>In Q2, we once again beat our financial targets on revenue, profit and earnings per share as we have every quarter for the ninth quarter since our IPO. We have ambitions at ODDITY to become one of the biggest beauty companies in the world and to lead this huge profitable and underserved market. And we are moving at high speed towards this goal. In just 7 years since launching our first beauty brand in the U.S., ODDITY has transformed into a platform of soon-to-be 3 brands, spanning 4 categories and 6-plus markets. We have gone from pure makeup to then skin and hair and now offering medical-grade prescription and OTC products with our upcoming launch of Brand 3.</td><td>2ë¶„ê¸°ì— ì €í¬ëŠ” IPO ì´í›„ 9ë¶„ê¸° ì—°ì†ìœ¼ë¡œ ë§¤ ë¶„ê¸°ë§ˆë‹¤ ê·¸ë˜ì™”ë“¯ì´, ë§¤ì¶œ, ì´ìµ, ì£¼ë‹¹ìˆœì´ìµì—ì„œ ë‹¤ì‹œ í•œë²ˆ ì¬ë¬´ ëª©í‘œë¥¼ ìƒíšŒí–ˆìŠµë‹ˆë‹¤. ODDITYëŠ” ì„¸ê³„ ìµœëŒ€ ë·°í‹° ê¸°ì—… ì¤‘ í•˜ë‚˜ê°€ ë˜ì–´ ì´ ê±°ëŒ€í•˜ê³  ìˆ˜ìµì„± ë†’ìœ¼ë©° ì„œë¹„ìŠ¤ê°€ ë¶€ì¡±í•œ ì‹œì¥ì„ ì„ ë„í•˜ê² ë‹¤ëŠ” í¬ë¶€ë¥¼ ê°€ì§€ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì €í¬ëŠ” ì´ ëª©í‘œë¥¼ í–¥í•´ ë¹ ë¥¸ ì†ë„ë¡œ ë‚˜ì•„ê°€ê³  ìˆìŠµë‹ˆë‹¤. ë¯¸êµ­ì—ì„œ ì²« ë²ˆì§¸ ë·°í‹° ë¸Œëœë“œë¥¼ ì¶œì‹œí•œ ì§€ ë¶ˆê³¼ 7ë…„ ë§Œì—, ODDITYëŠ” ê³§ 3ê°œ ë¸Œëœë“œ, 4ê°œ ì¹´í…Œê³ ë¦¬, 6ê°œ ì´ìƒì˜ ì‹œì¥ì— ê±¸ì¹œ í”Œë«í¼ìœ¼ë¡œ ë³€ëª¨í–ˆìŠµë‹ˆë‹¤. ì €í¬ëŠ” ìˆœìˆ˜ ë©”ì´í¬ì—…ì—ì„œ ì‹œì‘í•´ ìŠ¤í‚¨ì¼€ì–´ì™€ í—¤ì–´ì¼€ì–´ë¡œ í™•ì¥í–ˆê³ , ì´ì œ ê³§ ì¶œì‹œë  ë¸Œëœë“œ 3ë¥¼ í†µí•´ ì˜ë£Œê¸‰ ì²˜ë°©ì „ ë° ì¼ë°˜ì˜ì•½í’ˆì„ ì œê³µí•˜ê²Œ ë©ë‹ˆë‹¤.</td></tr>
<tr><td>And just as we unlock beauty online, we are now turning our sights to health care, another huge market where the consumer is unhappy and the opportunity is massive. I will share more on our plans for Brand 3 in a moment. Every year, we push our teams to innovate to expand our capabilities and grow the reach of our business. And you can see based on the results that we are doing a good job so far. It starts with the fact that we operate in a healthy, attractive market, huge in size where technology can drive big improvements for consumer and where the unit economics are strong. And it continues with our deliberate focus on the most attractive and durable vectors of growth.</td><td>ê·¸ë¦¬ê³  ì˜¨ë¼ì¸ì—ì„œ ë·°í‹°ë¥¼ í˜ì‹ í•œ ê²ƒì²˜ëŸ¼, ì´ì œ ìš°ë¦¬ëŠ” í—¬ìŠ¤ì¼€ì–´ë¡œ ì‹œì„ ì„ ëŒë¦¬ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŠ” ì†Œë¹„ìë“¤ì´ ë¶ˆë§Œì¡±ìŠ¤ëŸ¬ì›Œí•˜ê³  ê¸°íšŒê°€ ë§‰ëŒ€í•œ ë˜ ë‹¤ë¥¸ ê±°ëŒ€í•œ ì‹œì¥ì…ë‹ˆë‹¤. ì ì‹œ í›„ Brand 3ì— ëŒ€í•œ ìš°ë¦¬ì˜ ê³„íšì„ ë” ìì„¸íˆ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ë§¤ë…„ ìš°ë¦¬ëŠ” íŒ€ë“¤ì´ í˜ì‹ í•˜ì—¬ ì—­ëŸ‰ì„ í™•ì¥í•˜ê³  ì‚¬ì—…ì˜ ë„ë‹¬ ë²”ìœ„ë¥¼ ë„“íˆë„ë¡ ë…ë ¤í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì§€ê¸ˆê¹Œì§€ì˜ ê²°ê³¼ë¥¼ ë³´ì‹œë©´ ìš°ë¦¬ê°€ ì˜í•´ë‚´ê³  ìˆë‹¤ëŠ” ê²ƒì„ ì•Œ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì´ëŠ” ìš°ë¦¬ê°€ ê±´ì „í•˜ê³  ë§¤ë ¥ì ì¸ ì‹œì¥ì—ì„œ ìš´ì˜í•˜ê³  ìˆë‹¤ëŠ” ì‚¬ì‹¤ì—ì„œ ì‹œì‘ë©ë‹ˆë‹¤. ì´ ì‹œì¥ì€ ê·œëª¨ê°€ ê±°ëŒ€í•˜ê³ , ê¸°ìˆ ì´ ì†Œë¹„ìì—ê²Œ í° ê°œì„ ì„ ê°€ì ¸ë‹¤ì¤„ ìˆ˜ ìˆìœ¼ë©°, ë‹¨ìœ„ ê²½ì œì„±ì´ ê²¬ê³ í•œ ì‹œì¥ì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì´ëŠ” ê°€ì¥ ë§¤ë ¥ì ì´ê³  ì§€ì† ê°€ëŠ¥í•œ ì„±ì¥ ë™ë ¥ì— ëŒ€í•œ ìš°ë¦¬ì˜ ì˜ë„ì ì¸ ì§‘ì¤‘ìœ¼ë¡œ ì´ì–´ì§‘ë‹ˆë‹¤.</td></tr>
<tr><td>First, the expansion of online, which we expect will grow to be the largest channel in our industry. The investments we made years ago in data and technology allow us to be a leading direct-to-consumer company in beauty today, and we continue to invest in technology to strengthen our future. Second, consumer demand for high efficacy products. On that front, we are making big investments in pharma-grade technology at ODDITY Labs to discover breakthrough molecules and delivery systems. Beyond the sheer magnitude of our growth this year is the quality of that growth. It comes alongside strong profitability and cash flow and is fueled by each of our growth pillars.</td><td>ì²«ì§¸, ì˜¨ë¼ì¸ í™•ì¥ì…ë‹ˆë‹¤. ì˜¨ë¼ì¸ì€ ìš°ë¦¬ ì—…ê³„ì—ì„œ ê°€ì¥ í° ì±„ë„ë¡œ ì„±ì¥í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒë©ë‹ˆë‹¤. ìˆ˜ë…„ ì „ ë°ì´í„°ì™€ ê¸°ìˆ ì— ëŒ€í•œ íˆ¬ì ë•ë¶„ì— ì˜¤ëŠ˜ë‚  ë·°í‹° ë¶„ì•¼ì—ì„œ ì„ ë„ì ì¸ ì§ì ‘ ì†Œë¹„ì ëŒ€ìƒ(D2C) ê¸°ì—…ì´ ë  ìˆ˜ ìˆì—ˆìœ¼ë©°, ë¯¸ë˜ë¥¼ ê°•í™”í•˜ê¸° ìœ„í•´ ê¸°ìˆ ì— ì§€ì†ì ìœ¼ë¡œ íˆ¬ìí•˜ê³  ìˆìŠµë‹ˆë‹¤. ë‘˜ì§¸, ê³ íš¨ëŠ¥ ì œí’ˆì— ëŒ€í•œ ì†Œë¹„ì ìˆ˜ìš”ì…ë‹ˆë‹¤. ì´ ë¶€ë¶„ì—ì„œ ìš°ë¦¬ëŠ” ODDITY Labsì—ì„œ í˜ì‹ ì ì¸ ë¶„ìì™€ ì „ë‹¬ ì‹œìŠ¤í…œì„ ë°œê²¬í•˜ê¸° ìœ„í•´ ì œì•½ ë“±ê¸‰ ê¸°ìˆ ì— ëŒ€ê·œëª¨ íˆ¬ìë¥¼ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì˜¬í•´ ìš°ë¦¬ ì„±ì¥ì˜ ìˆœìˆ˜í•œ ê·œëª¨ë¥¼ ë„˜ì–´ì„œëŠ” ê²ƒì€ ê·¸ ì„±ì¥ì˜ ì§ˆì…ë‹ˆë‹¤. ì´ëŠ” ê°•ë ¥í•œ ìˆ˜ìµì„±ê³¼ í˜„ê¸ˆíë¦„ê³¼ í•¨ê»˜ ë‚˜íƒ€ë‚˜ë©°, ìš°ë¦¬ì˜ ê° ì„±ì¥ ë™ë ¥ì— ì˜í•´ ê²¬ì¸ë˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>This includes double-digit online growth in both IL MAKIAGE and SpoiledChild, generating growth both in the U.S. and international and scaling our skin portfolio, which remains on track to approach 40% of IL MAKIAGE's revenue this year. These drivers taken altogether allow us to sustain market share gains and outperform our competitors. The excellent first half financial performance we delivered this year sets the stage for a strong finish to 2025. As we have discussed, the second half of the year is highly driven by our large backlog of repeat where we have good visibility.</td><td>ì´ëŠ” IL MAKIAGEì™€ SpoiledChild ëª¨ë‘ì—ì„œ ë‘ ìë¦¿ìˆ˜ ì˜¨ë¼ì¸ ì„±ì¥ì„ í¬í•¨í•˜ì—¬, ë¯¸êµ­ê³¼ í•´ì™¸ ëª¨ë‘ì—ì„œ ì„±ì¥ì„ ì°½ì¶œí•˜ê³  ìˆìœ¼ë©°, ì˜¬í•´ IL MAKIAGE ë§¤ì¶œì˜ 40%ì— ê·¼ì ‘í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒë˜ëŠ” ìŠ¤í‚¨ì¼€ì–´ í¬íŠ¸í´ë¦¬ì˜¤ë¥¼ í™•ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ì„±ì¥ ë™ë ¥ë“¤ì„ ì¢…í•©í•˜ë©´ ì‹œì¥ ì ìœ ìœ¨ í™•ëŒ€ë¥¼ ì§€ì†í•˜ê³  ê²½ìŸì‚¬ë“¤ì„ ëŠ¥ê°€í•˜ëŠ” ì„±ê³¼ë¥¼ ê±°ë‘˜ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì˜¬í•´ ìƒë°˜ê¸°ì— ë‹¬ì„±í•œ ìš°ìˆ˜í•œ ì¬ë¬´ ì„±ê³¼ëŠ” 2025ë…„ ê°•ë ¥í•œ ë§ˆë¬´ë¦¬ë¥¼ ìœ„í•œ ë°œíŒì„ ë§ˆë ¨í•´ ì¤ë‹ˆë‹¤. ì•ì„œ ë…¼ì˜í•œ ë°”ì™€ ê°™ì´, í•˜ë°˜ê¸°ëŠ” ê°€ì‹œì„±ì´ í™•ë³´ëœ ëŒ€ê·œëª¨ ë¦¬í”¼íŠ¸ ì£¼ë¬¸ ì”ê³ ì— í¬ê²Œ ì¢Œìš°ë©ë‹ˆë‹¤.</td></tr>
<tr><td>Therefore, as is customary for us at this time of the year, our teams have pivoted their focus into 2026, where we are once again preparing, testing and iterating our incremental growth drivers for another strong year. While many of our teams work hard on 2026, the biggest focus for me and my sister are long-term initiatives that will allow us to continue compounding for the decades to come. This includes investments in technology, new brands and ODDITY Labs. So let's dive deeper into our multiyear growth drivers. The first is growing our existing brands. IL MAKIAGE remains on track to reach $1 billion revenue in 2028.</td><td>ë”°ë¼ì„œ ë§¤ë…„ ì´ë§˜ë•Œ ê´€ë¡€ì ìœ¼ë¡œ í•˜ë“¯ì´, ì €í¬ íŒ€ë“¤ì€ 2026ë…„ìœ¼ë¡œ ì´ˆì ì„ ì „í™˜í•˜ì—¬ ë˜ ë‹¤ë¥¸ ê°•ë ¥í•œ í•œ í•´ë¥¼ ìœ„í•œ ì ì§„ì  ì„±ì¥ ë™ë ¥ì„ ë‹¤ì‹œ í•œë²ˆ ì¤€ë¹„í•˜ê³ , í…ŒìŠ¤íŠ¸í•˜ë©°, ë°˜ë³µ ê°œì„ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë§ì€ íŒ€ë“¤ì´ 2026ë…„ì„ ìœ„í•´ ì—´ì‹¬íˆ ì¼í•˜ê³  ìˆëŠ” ê°€ìš´ë°, ì €ì™€ ì œ ìë§¤ê°€ ê°€ì¥ ì§‘ì¤‘í•˜ê³  ìˆëŠ” ê²ƒì€ ì•ìœ¼ë¡œ ìˆ˜ì‹­ ë…„ê°„ ì§€ì†ì ì¸ ë³µë¦¬ ì„±ì¥ì„ ê°€ëŠ¥í•˜ê²Œ í•  ì¥ê¸°ì  ì´ë‹ˆì…”í‹°ë¸Œì…ë‹ˆë‹¤. ì—¬ê¸°ì—ëŠ” ê¸°ìˆ , ì‹ ê·œ ë¸Œëœë“œ, ê·¸ë¦¬ê³  ODDITY Labsì— ëŒ€í•œ íˆ¬ìê°€ í¬í•¨ë©ë‹ˆë‹¤. ê·¸ëŸ¼ ì €í¬ì˜ ë‹¤ë…„ê°„ ì„±ì¥ ë™ë ¥ì— ëŒ€í•´ ë” ìì„¸íˆ ì‚´í´ë³´ê² ìŠµë‹ˆë‹¤. ì²« ë²ˆì§¸ëŠ” ê¸°ì¡´ ë¸Œëœë“œì˜ ì„±ì¥ì…ë‹ˆë‹¤. IL MAKIAGEëŠ” 2028ë…„ ë§¤ì¶œ 10ì–µ ë‹¬ëŸ¬ ë‹¬ì„± ëª©í‘œë¥¼ ìˆœì¡°ë¡­ê²Œ ì§„í–‰í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>International continues to be a highlight for us as we put increased focus on scaling this big opportunity even as we continue to grow in the U.S. International represented 15% of ODDITY business in 2024, driven by IL MAKIAGE, but for our competitors, it is closer to 70% of their business. In addition, we continue to win with IL MAKIAGE SKIN, which, as I mentioned, is expected to approach 40% of IL MAKIAGE revenue this year with more growth ahead. SpoiledChild is also having great year so far in 2025 with more runway ahead. The brand remains on track to cross $200 million of revenue this year after launching only 3 years ago in 2022.</td><td>êµ­ì œ ì‚¬ì—…ì€ ë¯¸êµ­ì—ì„œì˜ ì§€ì†ì ì¸ ì„±ì¥ê³¼ í•¨ê»˜ ì´ í° ê¸°íšŒë¥¼ í™•ëŒ€í•˜ëŠ” ë° ì§‘ì¤‘í•˜ê³  ìˆì–´ ì—¬ì „íˆ ìš°ë¦¬ì˜ í•˜ì´ë¼ì´íŠ¸ì…ë‹ˆë‹¤. 2024ë…„ êµ­ì œ ì‚¬ì—…ì€ IL MAKIAGEë¥¼ ì¤‘ì‹¬ìœ¼ë¡œ ODDITY ì „ì²´ ì‚¬ì—…ì˜ 15%ë¥¼ ì°¨ì§€í–ˆì§€ë§Œ, ê²½ìŸì‚¬ë“¤ì˜ ê²½ìš° ì‚¬ì—…ì˜ ì•½ 70%ì— ê°€ê¹ìŠµë‹ˆë‹¤. ë˜í•œ ì•ì„œ ì–¸ê¸‰í–ˆë“¯ì´ ì˜¬í•´ IL MAKIAGE ë§¤ì¶œì˜ 40%ì— ê·¼ì ‘í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒë˜ë©° í–¥í›„ ë” ë§ì€ ì„±ì¥ì´ ê¸°ëŒ€ë˜ëŠ” IL MAKIAGE SKINìœ¼ë¡œ ì§€ì†ì ì¸ ì„±ê³¼ë¥¼ ê±°ë‘ê³  ìˆìŠµë‹ˆë‹¤. SpoiledChild ì—­ì‹œ 2025ë…„ í˜„ì¬ê¹Œì§€ í›Œë¥­í•œ í•œ í•´ë¥¼ ë³´ë‚´ê³  ìˆìœ¼ë©° ì•ìœ¼ë¡œë„ ë” ë§ì€ ì„±ì¥ ì—¬ë ¥ì´ ìˆìŠµë‹ˆë‹¤. ì´ ë¸Œëœë“œëŠ” 2022ë…„ ì¶œì‹œ í›„ ë¶ˆê³¼ 3ë…„ ë§Œì— ì˜¬í•´ ë§¤ì¶œ 2ì–µ ë‹¬ëŸ¬ë¥¼ ëŒíŒŒí•  ê¶¤ë„ì— ì˜¬ë¼ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Our second key growth driver is new brand launches, and we are on schedule to launch Brand 3 this year and Brand 4 next year. Brand 3 will mark our first entrance into the medical grade space, starting in dermatology and giving our users access to OTC and prescription products. This unlocks an entirely new market for ODDITY. The third growth driver is ODDITY Labs, where we are working to create the world's highest efficacy products by bringing real science at high scale to our industry and discover game-changing molecules, ingredients and delivery systems. We continue to make progress building the team, the processes and the partnerships to achieve our goals.</td><td>ìš°ë¦¬ì˜ ë‘ ë²ˆì§¸ í•µì‹¬ ì„±ì¥ ë™ë ¥ì€ ì‹ ê·œ ë¸Œëœë“œ ì¶œì‹œì´ë©°, ì˜¬í•´ ë¸Œëœë“œ 3ì„, ë‚´ë…„ì— ë¸Œëœë“œ 4ë¥¼ ì¶œì‹œí•  ì˜ˆì •ëŒ€ë¡œ ì§„í–‰í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë¸Œëœë“œ 3ì€ í”¼ë¶€ê³¼ë¥¼ ì‹œì‘ìœ¼ë¡œ ì˜ë£Œìš© ë“±ê¸‰ ì˜ì—­ì— ì²« ì§„ì¶œí•˜ëŠ” ê²ƒìœ¼ë¡œ, ì‚¬ìš©ìë“¤ì—ê²Œ ì¼ë°˜ì˜ì•½í’ˆê³¼ ì „ë¬¸ì˜ì•½í’ˆì— ëŒ€í•œ ì ‘ê·¼ì„ ì œê³µí•  ê²ƒì…ë‹ˆë‹¤. ì´ëŠ” ODDITYì—ê²Œ ì™„ì „íˆ ìƒˆë¡œìš´ ì‹œì¥ì„ ì—´ì–´ì¤ë‹ˆë‹¤. ì„¸ ë²ˆì§¸ ì„±ì¥ ë™ë ¥ì€ ODDITY Labsì…ë‹ˆë‹¤. ì—¬ê¸°ì„œ ìš°ë¦¬ëŠ” ì—…ê³„ì— ëŒ€ê·œëª¨ ì‹¤ì§ˆì ì¸ ê³¼í•™ì„ ë„ì…í•˜ì—¬ ì„¸ê³„ ìµœê³  íš¨ëŠ¥ì˜ ì œí’ˆì„ ë§Œë“¤ê³ , ê²Œì„ ì²´ì¸ì €ê°€ ë  ë¶„ì, ì„±ë¶„ ë° ì „ë‹¬ ì‹œìŠ¤í…œì„ ë°œê²¬í•˜ê¸° ìœ„í•´ ë…¸ë ¥í•˜ê³  ìˆìŠµë‹ˆë‹¤. ìš°ë¦¬ì˜ ëª©í‘œ ë‹¬ì„±ì„ ìœ„í•´ íŒ€, í”„ë¡œì„¸ìŠ¤, íŒŒíŠ¸ë„ˆì‹­ êµ¬ì¶•ì—ì„œ ì§€ì†ì ìœ¼ë¡œ ì§„ì „ì„ ì´ë£¨ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>We have some proprietary molecules in development for Brands 3 and 4 for near-term rollout, while we are developing molecules and delivery systems for the long term with big potential. Turning now to more details on Brand 3, where we remain on track for our formal launch in Q4 of this year. Just as we use technology and direct-to-consumer model to transform beauty, we are turning our sights with Brand 3 on health care. Our goal is to help users solving their medical problems with minimal hassle and treatment iterations. Diagnosis, treatment matching and tracking all online without going to doctor office and pharmacy.</td><td>ë¸Œëœë“œ 3ê³¼ 4ë¥¼ ìœ„í•œ ë…ì  ë¶„ìë“¤ì„ ë‹¨ê¸° ì¶œì‹œë¥¼ ìœ„í•´ ê°œë°œ ì¤‘ì´ë©°, ë™ì‹œì— í° ì ì¬ë ¥ì„ ê°€ì§„ ì¥ê¸°ì ì¸ ë¶„ìì™€ ì „ë‹¬ ì‹œìŠ¤í…œì„ ê°œë°œí•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ì œ ë¸Œëœë“œ 3ì— ëŒ€í•œ ë” ìì„¸í•œ ë‚´ìš©ìœ¼ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤. ì˜¬í•´ 4ë¶„ê¸° ì •ì‹ ì¶œì‹œ ê³„íšì— ì°¨ì§ˆ ì—†ì´ ì§„í–‰ë˜ê³  ìˆìŠµë‹ˆë‹¤. ê¸°ìˆ ê³¼ ì§ì ‘ ì†Œë¹„ì ëª¨ë¸ì„ í™œìš©í•´ ë·°í‹° ì‚°ì—…ì„ ë³€í™”ì‹œí‚¨ ê²ƒì²˜ëŸ¼, ë¸Œëœë“œ 3ë¥¼ í†µí•´ í—¬ìŠ¤ì¼€ì–´ ë¶„ì•¼ë¡œ ì‹œì„ ì„ ëŒë¦¬ê³  ìˆìŠµë‹ˆë‹¤. ì €í¬ ëª©í‘œëŠ” ì‚¬ìš©ìë“¤ì´ ìµœì†Œí•œì˜ ë²ˆê±°ë¡œì›€ê³¼ ì¹˜ë£Œ ë°˜ë³µìœ¼ë¡œ ì˜ë£Œ ë¬¸ì œë¥¼ í•´ê²°í•  ìˆ˜ ìˆë„ë¡ ë•ëŠ” ê²ƒì…ë‹ˆë‹¤. ì§„ë‹¨, ì¹˜ë£Œ ë§¤ì¹­, ì¶”ì  ê´€ë¦¬ë¥¼ ëª¨ë‘ ì˜¨ë¼ì¸ìœ¼ë¡œ ì œê³µí•˜ì—¬ ë³‘ì›ì´ë‚˜ ì•½êµ­ì— ê°€ì§€ ì•Šì•„ë„ ë˜ë„ë¡ í•˜ëŠ” ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>We are starting with dermatology and planning new expansion categories for the future. Dermatology is an attractive starting point for us. First, it's large with huge reach. Around 50 million Americans are impacted by acne, around 30 million from eczema. These consumers were unhappy and underserved with attractive potential LTVs. And many of these consumers are already in our user base, which makes it a natural place for us to start. Around 50% of our 60 million-plus users report suffering from skin issues like acne, eczema and dark spots. And second, dermatology is an area with market share that we believe our technology can fit.</td><td>ì €í¬ëŠ” í”¼ë¶€ê³¼ë¡œ ì‹œì‘í•˜ì—¬ í–¥í›„ ìƒˆë¡œìš´ í™•ì¥ ì¹´í…Œê³ ë¦¬ë¥¼ ê³„íší•˜ê³  ìˆìŠµë‹ˆë‹¤. í”¼ë¶€ê³¼ëŠ” ì €í¬ì—ê²Œ ë§¤ë ¥ì ì¸ ì¶œë°œì ì…ë‹ˆë‹¤. ì²«ì§¸, ì‹œì¥ ê·œëª¨ê°€ í¬ê³  ë„ë‹¬ ë²”ìœ„ê°€ ë„“ìŠµë‹ˆë‹¤. ì•½ 5ì²œë§Œ ëª…ì˜ ë¯¸êµ­ì¸ì´ ì—¬ë“œë¦„ìœ¼ë¡œ, ì•½ 3ì²œë§Œ ëª…ì´ ìŠµì§„ìœ¼ë¡œ ê³ í†µë°›ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ì†Œë¹„ìë“¤ì€ ë¶ˆë§Œì¡±ìŠ¤ëŸ½ê³  ì¶©ë¶„í•œ ì„œë¹„ìŠ¤ë¥¼ ë°›ì§€ ëª»í•˜ê³  ìˆìœ¼ë©°, ë§¤ë ¥ì ì¸ ì ì¬ ê³ ê°ìƒì• ê°€ì¹˜(LTV)ë¥¼ ë³´ìœ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì´ëŸ¬í•œ ì†Œë¹„ìë“¤ ì¤‘ ìƒë‹¹ìˆ˜ê°€ ì´ë¯¸ ì €í¬ ì‚¬ìš©ì ê¸°ë°˜ì— í¬í•¨ë˜ì–´ ìˆì–´, ì €í¬ê°€ ì‹œì‘í•˜ê¸°ì— ìì—°ìŠ¤ëŸ¬ìš´ ì˜ì—­ì…ë‹ˆë‹¤. 6ì²œë§Œ ëª… ì´ìƒì˜ ì‚¬ìš©ì ì¤‘ ì•½ 50%ê°€ ì—¬ë“œë¦„, ìŠµì§„, ë‹¤í¬ìŠ¤íŒŸê³¼ ê°™ì€ í”¼ë¶€ ë¬¸ì œë¡œ ê³ ìƒí•˜ê³  ìˆë‹¤ê³  ë³´ê³ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë‘˜ì§¸, í”¼ë¶€ê³¼ëŠ” ì €í¬ ê¸°ìˆ ì´ ì í•©í•  ìˆ˜ ìˆë‹¤ê³  ë¯¿ëŠ” ì‹œì¥ ì ìœ ìœ¨ì„ ê°€ì§„ ì˜ì—­ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Our data shows that consumers are unhappy with current solutions. Drug stores offer generalized low-efficacy products that don't solve their issues. Dermatologists are a tough to access high friction experience. It costs $300 for dermatologist visit before even paying for the treatment itself. And the entire process is inconvenient. Going to dermatologist takes 2 hours of person's time on average. Over 2/3 of Americans counties don't have a practicing dermatologists at all. Online is a huge opportunity, yet no one has done it in the right way in our view. So we are taking on the category with an online model and entirely new playbook.</td><td>ì €í¬ ë°ì´í„°ì— ë”°ë¥´ë©´ ì†Œë¹„ìë“¤ì€ í˜„ì¬ ì†”ë£¨ì…˜ì— ë§Œì¡±í•˜ì§€ ì•Šê³  ìˆìŠµë‹ˆë‹¤. ì•½êµ­ì—ì„œëŠ” ì¼ë°˜í™”ëœ ì €íš¨ëŠ¥ ì œí’ˆë“¤ì„ ì œê³µí•˜ëŠ”ë°, ì´ëŠ” ê³ ê°ë“¤ì˜ ë¬¸ì œë¥¼ í•´ê²°í•˜ì§€ ëª»í•©ë‹ˆë‹¤. í”¼ë¶€ê³¼ ì „ë¬¸ì˜ëŠ” ì ‘ê·¼í•˜ê¸° ì–´ë µê³  ë²ˆê±°ë¡œìš´ ê²½í—˜ì„ ì œê³µí•©ë‹ˆë‹¤. ì¹˜ë£Œë¹„ë¥¼ ì§€ë¶ˆí•˜ê¸°ë„ ì „ì— í”¼ë¶€ê³¼ ì§„ë£Œë¹„ë§Œ 300ë‹¬ëŸ¬ê°€ ì†Œìš”ë©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì „ì²´ ê³¼ì •ì´ ë¶ˆí¸í•©ë‹ˆë‹¤. í”¼ë¶€ê³¼ì— ê°€ëŠ” ê²ƒì€ í‰ê· ì ìœ¼ë¡œ ê°œì¸ì˜ ì‹œê°„ì„ 2ì‹œê°„ì´ë‚˜ ì†Œìš”ì‹œí‚µë‹ˆë‹¤. ë¯¸êµ­ ì¹´ìš´í‹°ì˜ 2/3 ì´ìƒì—ëŠ” ê°œì—… í”¼ë¶€ê³¼ ì „ë¬¸ì˜ê°€ ì•„ì˜ˆ ì—†ìŠµë‹ˆë‹¤. ì˜¨ë¼ì¸ì€ ê±°ëŒ€í•œ ê¸°íšŒì´ì§€ë§Œ, ì €í¬ê°€ ë³´ê¸°ì—ëŠ” ì•„ë¬´ë„ ì˜¬ë°”ë¥¸ ë°©ì‹ìœ¼ë¡œ ì ‘ê·¼í•˜ì§€ ì•Šì•˜ìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ì €í¬ëŠ” ì˜¨ë¼ì¸ ëª¨ë¸ê³¼ ì™„ì „íˆ ìƒˆë¡œìš´ í”Œë ˆì´ë¶ìœ¼ë¡œ ì´ ì¹´í…Œê³ ë¦¬ì— ë„ì „í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>When determining our strategy, we always start from the first principles on how to win the category rather than copying others. Our direct relationship with consumers gives us better understanding into the problems they face and an edge in finding solutions. As one example, we are investing in personalization to make it a big differentiator between us and our competitors. I will walk you through how it comes together in the acne category. It starts with the product offering itself. Each consumer has unique problems and preferences.</td><td>ì „ëµì„ ìˆ˜ë¦½í•  ë•Œ, ì €í¬ëŠ” í•­ìƒ ë‹¤ë¥¸ ì—…ì²´ë¥¼ ëª¨ë°©í•˜ê¸°ë³´ë‹¤ëŠ” í•´ë‹¹ ì¹´í…Œê³ ë¦¬ì—ì„œ ì–´ë–»ê²Œ ìŠ¹ë¦¬í•  ê²ƒì¸ê°€ì— ëŒ€í•œ ê¸°ë³¸ ì›ì¹™ë¶€í„° ì‹œì‘í•©ë‹ˆë‹¤. ì†Œë¹„ìì™€ì˜ ì§ì ‘ì ì¸ ê´€ê³„ëŠ” ê·¸ë“¤ì´ ì§ë©´í•œ ë¬¸ì œì— ëŒ€í•œ ë” ë‚˜ì€ ì´í•´ë¥¼ ì œê³µí•˜ë©°, ì†”ë£¨ì…˜ì„ ì°¾ëŠ” ë° ìˆì–´ ê²½ìŸ ìš°ìœ„ë¥¼ ê°€ì ¸ë‹¤ ì¤ë‹ˆë‹¤. í•œ ê°€ì§€ ì˜ˆë¡œ, ì €í¬ëŠ” ê°œì¸í™”ë¥¼ ê²½ìŸì‚¬ì™€ ì €í¬ë¥¼ ì°¨ë³„í™”í•˜ëŠ” í° ìš”ì†Œë¡œ ë§Œë“¤ê¸° ìœ„í•´ íˆ¬ìí•˜ê³  ìˆìŠµë‹ˆë‹¤. ì—¬ë“œë¦„ ì¹´í…Œê³ ë¦¬ì—ì„œ ì´ê²ƒì´ ì–´ë–»ê²Œ ê²°í•©ë˜ëŠ”ì§€ ì„¤ëª…ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ì´ëŠ” ì œí’ˆ ì œê³µ ìì²´ë¶€í„° ì‹œì‘ë©ë‹ˆë‹¤. ê° ì†Œë¹„ìëŠ” ê³ ìœ í•œ ë¬¸ì œì™€ ì„ í˜¸ë„ë¥¼ ê°€ì§€ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Some have mild acne, others struggle with inflammatory papules and pustules, deep cystic acne, hormonal breakouts or persistent truncal acne on their chest or back. Many of our competitors get this wrong and offer most customers the same treatment. By contrast, we have 20-plus user cohorts with unique treatment recommendations. These customized offering show a 50% improvement in the amount of satisfied testers compared to tretinoin alone based on internal work we have done. Next is our online experience, where we pair advanced computer-vision technology with doctor-developed protocols to deliver highly efficacious tailored treatments.</td><td>ì¼ë¶€ëŠ” ê°€ë²¼ìš´ ì—¬ë“œë¦„ì„, ë‹¤ë¥¸ ì¼ë¶€ëŠ” ì—¼ì¦ì„± êµ¬ì§„ê³¼ ë†í¬, ê¹Šì€ ë‚­í¬ì„± ì—¬ë“œë¦„, í˜¸ë¥´ëª¬ì„± ì—¬ë“œë¦„ ë˜ëŠ” ê°€ìŠ´ì´ë‚˜ ë“±ì— ì§€ì†ì ìœ¼ë¡œ ë‚˜íƒ€ë‚˜ëŠ” ëª¸í†µ ì—¬ë“œë¦„ìœ¼ë¡œ ê³ ìƒí•˜ê³  ìˆìŠµë‹ˆë‹¤. ì €í¬ ê²½ìŸì‚¬ë“¤ ì¤‘ ë‹¤ìˆ˜ëŠ” ì´ ì ì„ ì œëŒ€ë¡œ íŒŒì•…í•˜ì§€ ëª»í•˜ê³  ëŒ€ë¶€ë¶„ì˜ ê³ ê°ì—ê²Œ ë™ì¼í•œ ì¹˜ë£Œë²•ì„ ì œê³µí•©ë‹ˆë‹¤. ì´ì™€ ëŒ€ì¡°ì ìœ¼ë¡œ, ì €í¬ëŠ” ê³ ìœ í•œ ì¹˜ë£Œ ê¶Œì¥ì‚¬í•­ì„ ê°€ì§„ 20ê°œ ì´ìƒì˜ ì‚¬ìš©ì ì½”í˜¸íŠ¸ë¥¼ ë³´ìœ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ë§ì¶¤í˜• ì„œë¹„ìŠ¤ëŠ” ì €í¬ê°€ ìˆ˜í–‰í•œ ë‚´ë¶€ ì—°êµ¬ì— ë”°ë¥´ë©´ íŠ¸ë ˆí‹°ë…¸ì¸ ë‹¨ë… ì‚¬ìš© ëŒ€ë¹„ ë§Œì¡±í•œ í…ŒìŠ¤í„°ì˜ ë¹„ìœ¨ì—ì„œ 50% ê°œì„ ì„ ë³´ì—¬ì¤ë‹ˆë‹¤. ë‹¤ìŒì€ ì €í¬ì˜ ì˜¨ë¼ì¸ ê²½í—˜ìœ¼ë¡œ, ì²¨ë‹¨ ì»´í“¨í„° ë¹„ì „ ê¸°ìˆ ê³¼ ì˜ì‚¬ê°€ ê°œë°œí•œ í”„ë¡œí† ì½œì„ ê²°í•©í•˜ì—¬ ë§¤ìš° íš¨ê³¼ì ì¸ ë§ì¶¤í˜• ì¹˜ë£Œë¥¼ ì œê³µí•©ë‹ˆë‹¤.</td></tr>
<tr><td>And finally, in coaching to ensure high compliance through our mobile progress tracking app, where users stay consistently supported and on track with personalized guidance, photo-based progress monitoring and dynamic treatment adjustments tailored to their evolving needs. Overall, we are introducing innovation and access that we believe dermatology hasn't seen in decades. It is a huge benefit to consumers, and we believe it will transform the category. We will have more to report on Brand 3 after we officially launch later this year. Before handing over to Lindsay, I want to take a moment to reflect on our 2-year anniversary as a public company.</td><td>ë§ˆì§€ë§‰ìœ¼ë¡œ, ì½”ì¹­ ë¶€ë¬¸ì—ì„œëŠ” ëª¨ë°”ì¼ ì§„í–‰ìƒí™© ì¶”ì  ì•±ì„ í†µí•´ ë†’ì€ ìˆœì‘ë„ë¥¼ ë³´ì¥í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ ì•±ì„ í†µí•´ ì‚¬ìš©ìë“¤ì€ ê°œì¸ ë§ì¶¤í˜• ê°€ì´ë“œ, ì‚¬ì§„ ê¸°ë°˜ ì§„í–‰ìƒí™© ëª¨ë‹ˆí„°ë§, ê·¸ë¦¬ê³  ë³€í™”í•˜ëŠ” ìš”êµ¬ì‚¬í•­ì— ë§ì¶˜ ë™ì  ì¹˜ë£Œ ì¡°ì •ì„ í†µí•´ ì§€ì†ì ì¸ ì§€ì›ì„ ë°›ìœ¼ë©° ëª©í‘œë¥¼ ë‹¬ì„±í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì „ë°˜ì ìœ¼ë¡œ, ìš°ë¦¬ëŠ” í”¼ë¶€ê³¼ ë¶„ì•¼ì—ì„œ ìˆ˜ì‹­ ë…„ê°„ ë³¼ ìˆ˜ ì—†ì—ˆë˜ í˜ì‹ ê³¼ ì ‘ê·¼ì„±ì„ ë„ì…í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŠ” ì†Œë¹„ìë“¤ì—ê²Œ í° í˜œíƒì´ ë˜ë©°, ì´ ë¶„ì•¼ë¥¼ ë³€í™”ì‹œí‚¬ ê²ƒì´ë¼ê³  ë¯¿ìŠµë‹ˆë‹¤. ì˜¬í•´ í›„ë°˜ ê³µì‹ ì¶œì‹œ ì´í›„ Brand 3ì— ëŒ€í•´ ë” ë§ì€ ë‚´ìš©ì„ ë³´ê³ ë“œë¦¬ê² ìŠµë‹ˆë‹¤. Lindsayì—ê²Œ ë„˜ê¸°ê¸° ì „ì—, ìƒì¥ ê¸°ì—…ìœ¼ë¡œì„œì˜ 2ì£¼ë…„ì„ ë§ì´í•œ ì‹œì ì—ì„œ ì ì‹œ ë˜ëŒì•„ë³´ëŠ” ì‹œê°„ì„ ê°–ê³ ì í•©ë‹ˆë‹¤.</td></tr>
<tr><td>We are proud on our long-term partnerships we have made with investors since our IPO. They are built on the trust that comes with consistently executing our plans, no matter the market backdrop. As the founder, CEO and the largest shareholder of the company, the single most important thing for me is delivering on our promises to our shareholders. With that, I will turn it over to Lindsay. Lindsay Drucker Mann<br><br>Thanks, Oran. Let's turn to our second quarter results, which I'll refer to on an adjusted basis. You can find the full reconciliation to GAAP in our press release.</td><td>ì €í¬ëŠ” IPO ì´í›„ íˆ¬ììë“¤ê³¼ êµ¬ì¶•í•´ì˜¨ ì¥ê¸°ì ì¸ íŒŒíŠ¸ë„ˆì‹­ì„ ìë‘ìŠ¤ëŸ½ê²Œ ìƒê°í•©ë‹ˆë‹¤. ì´ëŸ¬í•œ ê´€ê³„ëŠ” ì‹œì¥ í™˜ê²½ì— ê´€ê³„ì—†ì´ ì¼ê´€ë˜ê²Œ ê³„íšì„ ì‹¤í–‰í•´ì˜¨ ê²ƒì—ì„œ ë‚˜ì˜¤ëŠ” ì‹ ë¢°ë¥¼ ë°”íƒ•ìœ¼ë¡œ êµ¬ì¶•ë˜ì—ˆìŠµë‹ˆë‹¤. ì°½ë¦½ìì´ì CEO, ê·¸ë¦¬ê³  íšŒì‚¬ì˜ ìµœëŒ€ ì£¼ì£¼ë¡œì„œ ì €ì—ê²Œ ê°€ì¥ ì¤‘ìš”í•œ ê²ƒì€ ì£¼ì£¼ë“¤ê³¼ì˜ ì•½ì†ì„ ì´í–‰í•˜ëŠ” ê²ƒì…ë‹ˆë‹¤. ì´ì œ Lindsayì—ê²Œ ë§ˆì´í¬ë¥¼ ë„˜ê¸°ê² ìŠµë‹ˆë‹¤.<br><br>Lindsay Drucker Mann<br><br>ê°ì‚¬í•©ë‹ˆë‹¤, Oran. ì¡°ì • ê¸°ì¤€ìœ¼ë¡œ ë§ì”€ë“œë¦´ 2ë¶„ê¸° ì‹¤ì ìœ¼ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤. GAAP ê¸°ì¤€ê³¼ì˜ ì™„ì „í•œ ì¡°ì • ë‚´ì—­ì€ ë³´ë„ìë£Œì—ì„œ í™•ì¸í•˜ì‹¤ ìˆ˜ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Q2 was another strong quarter for us, capping off a great first half of the year, which is our most critical moment for user acquisition. These results set us up for another record-breaking year in 2025. We grew net revenue by 25% in the second quarter to $241 million. This exceeded our guidance for revenue growth of between 22% and 24%. The strength was driven by double-digit online growth at both IL MAKIAGE and SpoiledChild. Net revenue growth was driven by an increase in orders, while average order value was down around 1%. Average order value was impacted by mix, including faster growth in international markets and an increase in the mix of repeat sales, both of which carry lower AOV.</td><td>2ë¶„ê¸°ëŠ” ì €í¬ì—ê²Œ ë˜ ë‹¤ë¥¸ ê°•ë ¥í•œ ë¶„ê¸°ì˜€ìœ¼ë©°, ì‚¬ìš©ì í™•ë³´ì— ìˆì–´ ê°€ì¥ ì¤‘ìš”í•œ ì‹œê¸°ì¸ ìƒë°˜ê¸°ë¥¼ í›Œë¥­í•˜ê²Œ ë§ˆë¬´ë¦¬í–ˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ì‹¤ì ì€ 2025ë…„ ë˜ ë‹¤ë¥¸ ê¸°ë¡ì ì¸ í•œ í•´ë¥¼ ìœ„í•œ ë°œíŒì„ ë§ˆë ¨í•´ ì£¼ì—ˆìŠµë‹ˆë‹¤. 2ë¶„ê¸° ìˆœë§¤ì¶œì€ 25% ì„±ì¥í•œ 2ì–µ 4,100ë§Œ ë‹¬ëŸ¬ë¥¼ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤. ì´ëŠ” 22%ì—ì„œ 24% ì‚¬ì´ì˜ ë§¤ì¶œ ì„±ì¥ë¥  ê°€ì´ë˜ìŠ¤ë¥¼ ìƒíšŒí•˜ëŠ” ìˆ˜ì¹˜ì…ë‹ˆë‹¤. ì´ëŸ¬í•œ ê°•ì„¸ëŠ” IL MAKIAGEì™€ SpoiledChild ëª¨ë‘ì—ì„œ ë‘ ìë¦¿ìˆ˜ ì˜¨ë¼ì¸ ì„±ì¥ì— í˜ì…ì€ ê²ƒì…ë‹ˆë‹¤. ìˆœë§¤ì¶œ ì„±ì¥ì€ ì£¼ë¬¸ ê±´ìˆ˜ ì¦ê°€ì— ì˜í•´ ê²¬ì¸ë˜ì—ˆìœ¼ë©°, í‰ê·  ì£¼ë¬¸ ê¸ˆì•¡ì€ ì•½ 1% ê°ì†Œí–ˆìŠµë‹ˆë‹¤. í‰ê·  ì£¼ë¬¸ ê¸ˆì•¡ì€ ë¯¹ìŠ¤ ë³€í™”ì˜ ì˜í–¥ì„ ë°›ì•˜ëŠ”ë°, ì—¬ê¸°ì—ëŠ” í•´ì™¸ ì‹œì¥ì—ì„œì˜ ë¹ ë¥¸ ì„±ì¥ê³¼ ì¬êµ¬ë§¤ ë¹„ì¤‘ ì¦ê°€ê°€ í¬í•¨ë˜ë©°, ì´ ë‘ ìš”ì†Œ ëª¨ë‘ ë‚®ì€ AOVë¥¼ ë³´ì…ë‹ˆë‹¤.</td></tr>
<tr><td>A bit more color on international. As Oran mentioned, our sales outside the United States represented around 15% of ODDITY's 2024 net revenue. This is driven by IL MAKIAGE, where we have operations in the U.K., Germany, Canada, Australia and Israel. We also conduct tests in prospective new countries and the revenue from these test markets flows through our P&L. On our Q4 '24 call, we discussed our plans to increase focus on IL MAKIAGE International. This has meant greater prioritization from our teams as well as increased acquisition spend. The strategic rationale for our increased focus is straightforward.</td><td>í•´ì™¸ ì‚¬ì—…ì— ëŒ€í•´ ì¢€ ë” ìì„¸íˆ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ì˜¤ë€ì´ ì–¸ê¸‰í–ˆë“¯ì´, ë¯¸êµ­ ì™¸ ë§¤ì¶œì€ ODDITYì˜ 2024ë…„ ìˆœë§¤ì¶œì˜ ì•½ 15%ë¥¼ ì°¨ì§€í–ˆìŠµë‹ˆë‹¤. ì´ëŠ” ì˜êµ­, ë…ì¼, ìºë‚˜ë‹¤, í˜¸ì£¼, ì´ìŠ¤ë¼ì—˜ì—ì„œ ì‚¬ì—…ì„ ìš´ì˜í•˜ê³  ìˆëŠ” IL MAKIAGEê°€ ê²¬ì¸í–ˆìŠµë‹ˆë‹¤. ë˜í•œ ì ì¬ì ì¸ ì‹ ê·œ êµ­ê°€ì—ì„œ í…ŒìŠ¤íŠ¸ë¥¼ ì§„í–‰í•˜ê³  ìˆìœ¼ë©°, ì´ëŸ¬í•œ í…ŒìŠ¤íŠ¸ ì‹œì¥ì—ì„œ ë°œìƒí•˜ëŠ” ë§¤ì¶œì€ ë‹¹ì‚¬ì˜ ì†ìµê³„ì‚°ì„œì— ë°˜ì˜ë©ë‹ˆë‹¤. 2024ë…„ 4ë¶„ê¸° ì‹¤ì ë°œí‘œì—ì„œ IL MAKIAGE í•´ì™¸ ì‚¬ì—…ì— ëŒ€í•œ ì§‘ì¤‘ë„ë¥¼ ë†’ì´ê² ë‹¤ëŠ” ê³„íšì„ ë…¼ì˜í–ˆìŠµë‹ˆë‹¤. ì´ëŠ” íŒ€ì˜ ìš°ì„ ìˆœìœ„ ì¡°ì •ê³¼ í•¨ê»˜ ê³ ê° íšë“ ì§€ì¶œ ì¦ê°€ë¥¼ ì˜ë¯¸í•©ë‹ˆë‹¤. ì§‘ì¤‘ë„ë¥¼ ë†’ì´ëŠ” ì „ëµì  ê·¼ê±°ëŠ” ëª…í™•í•©ë‹ˆë‹¤.</td></tr>
<tr><td>International is a meaningful revenue opportunity for us with great unit economics and a key driver in building IL MAKIAGE into a $1 billion revenue brand. The demand drivers for beauty online are similar overseas to what we see in the U.S. market today. Our technology platform works well in these countries. In fact, for markets like the U.K. and Australia, where we're already operating, we believe IL MAKIAGE is already the #1 or #2 largest online beauty brand. And we can see from incumbents that there is a huge potential for us. As Oran mentioned, they generate around 70% of revenue internationally versus our 15%.</td><td>í•´ì™¸ ì‚¬ì—…ì€ ìš°ìˆ˜í•œ ë‹¨ìœ„ ê²½ì œì„±ì„ ë°”íƒ•ìœ¼ë¡œ í•œ ì˜ë¯¸ ìˆëŠ” ë§¤ì¶œ ê¸°íšŒì´ë©°, IL MAKIAGEë¥¼ 10ì–µ ë‹¬ëŸ¬ ë§¤ì¶œ ë¸Œëœë“œë¡œ ì„±ì¥ì‹œí‚¤ëŠ” í•µì‹¬ ë™ë ¥ì…ë‹ˆë‹¤. ì˜¨ë¼ì¸ ë·°í‹° ì‹œì¥ì˜ ìˆ˜ìš” ë™ì¸ë“¤ì€ í•´ì™¸ì—ì„œë„ í˜„ì¬ ë¯¸êµ­ ì‹œì¥ì—ì„œ ë³´ëŠ” ê²ƒê³¼ ìœ ì‚¬í•©ë‹ˆë‹¤. ìš°ë¦¬ì˜ ê¸°ìˆ  í”Œë«í¼ì€ ì´ëŸ¬í•œ êµ­ê°€ë“¤ì—ì„œ ì˜ ì‘ë™í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì‹¤ì œë¡œ ìš°ë¦¬ê°€ ì´ë¯¸ ì§„ì¶œí•´ ìˆëŠ” ì˜êµ­ê³¼ í˜¸ì£¼ ê°™ì€ ì‹œì¥ì—ì„œëŠ” IL MAKIAGEê°€ ì´ë¯¸ 1ìœ„ ë˜ëŠ” 2ìœ„ì˜ ì˜¨ë¼ì¸ ë·°í‹° ë¸Œëœë“œë¼ê³  ë¯¿ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ê¸°ì¡´ ì—…ì²´ë“¤ì„ í†µí•´ ìš°ë¦¬ì—ê²Œ ì—„ì²­ë‚œ ì ì¬ë ¥ì´ ìˆìŒì„ í™•ì¸í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. Oranì´ ì–¸ê¸‰í–ˆë“¯ì´, ê·¸ë“¤ì€ ë§¤ì¶œì˜ ì•½ 70%ë¥¼ í•´ì™¸ì—ì„œ ì°½ì¶œí•˜ëŠ” ë°˜ë©´ ìš°ë¦¬ëŠ” 15%ì— ë¶ˆê³¼í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Results from our international push have been very strong, both in existing markets and prospective markets like France, more from us in international to come. Back in the U.S., IL MAKIAGE remains strong, continues to grow, and we expect more growth in the future. Moving down the P&L. Gross margin of 72.3% expanded 10 basis points year-over-year and exceeded our guidance of 70.5%. The delta versus our outlook was driven in part by better mix. We did see some initial flow-through of tariffs this quarter, which, as expected, were small.</td><td>í•´ì™¸ ì§„ì¶œ ê²°ê³¼ëŠ” ê¸°ì¡´ ì‹œì¥ê³¼ í”„ë‘ìŠ¤ì™€ ê°™ì€ ì ì¬ ì‹œì¥ ëª¨ë‘ì—ì„œ ë§¤ìš° ê°•ë ¥í•œ ì„±ê³¼ë¥¼ ë³´ì˜€ìœ¼ë©°, ì•ìœ¼ë¡œ í•´ì™¸ ì‚¬ì—…ì—ì„œ ë” ë§ì€ ì„±ê³¼ê°€ ìˆì„ ê²ƒìœ¼ë¡œ ì˜ˆìƒë©ë‹ˆë‹¤. ë¯¸êµ­ ë‚´ì—ì„œëŠ” IL MAKIAGEê°€ ì—¬ì „íˆ ê²¬ì¡°í•œ ì„±ì¥ì„¸ë¥¼ ì§€ì†í•˜ê³  ìˆìœ¼ë©°, í–¥í›„ì—ë„ ë” ë§ì€ ì„±ì¥ì„ ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤. <br><br>ì†ìµê³„ì‚°ì„œë¥¼ ì‚´í´ë³´ë©´, ë§¤ì¶œì´ì´ìµë¥ ì€ 72.3%ë¡œ ì „ë…„ ë™ê¸° ëŒ€ë¹„ 10bp í™•ëŒ€ë˜ì—ˆìœ¼ë©°, ë‹¹ì‚¬ì˜ ê°€ì´ë˜ìŠ¤ì¸ 70.5%ë¥¼ ìƒíšŒí–ˆìŠµë‹ˆë‹¤. ì „ë§ì¹˜ì™€ì˜ ì°¨ì´ëŠ” ë¶€ë¶„ì ìœ¼ë¡œ ë” ë‚˜ì€ ì œí’ˆ ë¯¹ìŠ¤ì— ê¸°ì¸í–ˆìŠµë‹ˆë‹¤. ì´ë²ˆ ë¶„ê¸°ì— ê´€ì„¸ì˜ ì´ˆê¸° ì˜í–¥ì„ ì¼ë¶€ í™•ì¸í–ˆëŠ”ë°, ì˜ˆìƒí–ˆë˜ ë°”ì™€ ê°™ì´ ê·¸ ê·œëª¨ëŠ” ì‘ì•˜ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Based on the information we have today, we continue to expect that tariffs will be less than 100 basis point headwind to our gross margin this year and will be a similarly manageable headwind in 2026. We delivered adjusted EBITDA of $70 million in the quarter, above our guidance of $65 million to $68 million. Adjusted EBITDA margin of 28.8% compressed by around 350 basis points, driven by planned growth investments. We remain focused on reinvesting in our business to support our long-term growth initiatives, including Brand 3, Brand 4, ODDITY Labs and our technology innovation. We delivered adjusted diluted earnings per share of $0.92 compared to our guidance of between $0.85 and $0.89.</td><td>í˜„ì¬ ë³´ìœ í•œ ì •ë³´ë¥¼ ë°”íƒ•ìœ¼ë¡œ, ê´€ì„¸ê°€ ì˜¬í•´ ë‹¹ì‚¬ ë§¤ì¶œì´ì´ìµë¥ ì— 100ë² ì´ì‹œìŠ¤í¬ì¸íŠ¸ ë¯¸ë§Œì˜ ì—­í’ìœ¼ë¡œ ì‘ìš©í•  ê²ƒìœ¼ë¡œ ê³„ì† ì˜ˆìƒí•˜ê³  ìˆìœ¼ë©°, 2026ë…„ì—ë„ ìœ ì‚¬í•˜ê²Œ ê´€ë¦¬ ê°€ëŠ¥í•œ ìˆ˜ì¤€ì˜ ì—­í’ì´ ë  ê²ƒìœ¼ë¡œ ì „ë§í•©ë‹ˆë‹¤. ë‹¹ ë¶„ê¸° ì¡°ì • EBITDAëŠ” 7ì²œë§Œ ë‹¬ëŸ¬ë¥¼ ê¸°ë¡í•˜ì—¬ ê°€ì´ë˜ìŠ¤ì¸ 6ì²œ5ë°±ë§Œ ë‹¬ëŸ¬ì—ì„œ 6ì²œ8ë°±ë§Œ ë‹¬ëŸ¬ë¥¼ ìƒíšŒí–ˆìŠµë‹ˆë‹¤. ì¡°ì • EBITDA ë§ˆì§„ì€ 28.8%ë¡œ ê³„íšëœ ì„±ì¥ íˆ¬ìë¡œ ì¸í•´ ì•½ 350ë² ì´ì‹œìŠ¤í¬ì¸íŠ¸ ì••ì¶•ë˜ì—ˆìŠµë‹ˆë‹¤. ë‹¹ì‚¬ëŠ” ë¸Œëœë“œ 3, ë¸Œëœë“œ 4, ODDITY Labs ë° ê¸°ìˆ  í˜ì‹ ì„ í¬í•¨í•œ ì¥ê¸° ì„±ì¥ ì´ë‹ˆì…”í‹°ë¸Œë¥¼ ì§€ì›í•˜ê¸° ìœ„í•´ ì‚¬ì—…ì— ì¬íˆ¬ìí•˜ëŠ” ë° ê³„ì† ì§‘ì¤‘í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì¡°ì • í¬ì„ ì£¼ë‹¹ìˆœì´ìµì€ 0.92ë‹¬ëŸ¬ë¥¼ ê¸°ë¡í•˜ì—¬ ê°€ì´ë˜ìŠ¤ì¸ 0.85ë‹¬ëŸ¬ì—ì„œ 0.89ë‹¬ëŸ¬ë¥¼ ìƒíšŒí–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Our adjusted EBITDA and EPS excludes approximately $10 million of share-based compensation. We continue to deliver very strong free cash<br><br>flow and free cash conversion, a clear reflection of the strength and quality of our business model. We generated $99 million of free cash flow in the first 6 months of 2025, converting more than 80% of our adjusted EBITDA into free cash. During the quarter, we issued our first ever convert as an exchangeable note through a U.S. subsidiary. The transaction was upsized on strong demand to $600 million, inclusive of the green shoe.</td><td>ë‹¹ì‚¬ì˜ ì¡°ì • EBITDAì™€ EPSëŠ” ì•½ 1ì²œë§Œ ë‹¬ëŸ¬ì˜ ì£¼ì‹ê¸°ì¤€ë³´ìƒì„ ì œì™¸í•œ ìˆ˜ì¹˜ì…ë‹ˆë‹¤. ë‹¹ì‚¬ëŠ” ì§€ì†ì ìœ¼ë¡œ ë§¤ìš° ê°•ë ¥í•œ ì‰ì—¬í˜„ê¸ˆíë¦„ê³¼ ì‰ì—¬í˜„ê¸ˆ ì „í™˜ìœ¨ì„ ë‹¬ì„±í•˜ê³  ìˆìœ¼ë©°, ì´ëŠ” ë‹¹ì‚¬ ë¹„ì¦ˆë‹ˆìŠ¤ ëª¨ë¸ì˜ ê°•ì ê³¼ í’ˆì§ˆì„ ëª…í™•íˆ ë³´ì—¬ì£¼ëŠ” ì§€í‘œì…ë‹ˆë‹¤. 2025ë…„ ìƒë°˜ê¸° 6ê°œì›” ë™ì•ˆ 9ì²œ 9ë°±ë§Œ ë‹¬ëŸ¬ì˜ ì‰ì—¬í˜„ê¸ˆíë¦„ì„ ì°½ì¶œí–ˆìœ¼ë©°, ì¡°ì • EBITDAì˜ 80% ì´ìƒì„ ì‰ì—¬í˜„ê¸ˆìœ¼ë¡œ ì „í™˜í–ˆìŠµë‹ˆë‹¤. í•´ë‹¹ ë¶„ê¸° ì¤‘ì—ëŠ” ë¯¸êµ­ ìíšŒì‚¬ë¥¼ í†µí•´ êµí™˜ì‚¬ì±„ í˜•íƒœë¡œ ìµœì´ˆì˜ ì „í™˜ì‚¬ì±„ë¥¼ ë°œí–‰í–ˆìŠµë‹ˆë‹¤. ì´ ê±°ë˜ëŠ” ê°•í•œ ìˆ˜ìš”ì— í˜ì…ì–´ ê·¸ë¦°ìŠˆ ì˜µì…˜ì„ í¬í•¨í•˜ì—¬ 6ì–µ ë‹¬ëŸ¬ë¡œ ì¦ì•¡ë˜ì—ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>The note is 0 coupon with a 5-year maturity, and we purchased a cap call at a cost of 10.5% of the offering size that limits dilution until the stock price approximately doubles. This offering allowed us to significantly increase our cash position, and we finished the quarter with $815 million of cash, cash equivalents and investments on our balance sheet with an additional $200 million available on our undrawn credit facilities. Our capital allocation strategy continues to be patient and opportunistic. As a reminder, our capital priorities are: number one, reinvesting in the business; number two, M&A; and number three, opportunistic buybacks.</td><td>ì´ ì±„ê¶Œì€ 5ë…„ ë§Œê¸° ë¬´ì´í‘œì±„ì´ë©°, ì£¼ê°€ê°€ ì•½ 2ë°°ê°€ ë  ë•Œê¹Œì§€ í¬ì„ì„ ì œí•œí•˜ëŠ” ìº¡ ì½œì„ ë°œí–‰ ê·œëª¨ì˜ 10.5% ë¹„ìš©ìœ¼ë¡œ ë§¤ì…í–ˆìŠµë‹ˆë‹¤. ì´ë²ˆ ë°œí–‰ì„ í†µí•´ í˜„ê¸ˆ í¬ì§€ì…˜ì„ í¬ê²Œ ëŠ˜ë¦´ ìˆ˜ ìˆì—ˆìœ¼ë©°, ë¶„ê¸° ë§ ê¸°ì¤€ìœ¼ë¡œ ëŒ€ì°¨ëŒ€ì¡°í‘œìƒ í˜„ê¸ˆ, í˜„ê¸ˆì„± ìì‚° ë° íˆ¬ììì‚°ì´ 8ì–µ 1,500ë§Œ ë‹¬ëŸ¬ì´ê³ , ë¯¸ì‚¬ìš© ì‹ ìš©í•œë„ì—ì„œ ì¶”ê°€ë¡œ 2ì–µ ë‹¬ëŸ¬ë¥¼ ì‚¬ìš©í•  ìˆ˜ ìˆì–´ ë¶„ê¸°ë¥¼ ë§ˆê°í–ˆìŠµë‹ˆë‹¤. ì €í¬ì˜ ìë³¸ ë°°ë¶„ ì „ëµì€ ê³„ì†í•´ì„œ ì‹ ì¤‘í•˜ê³  ê¸°íšŒì£¼ì˜ì ì¸ ì ‘ê·¼ì„ ìœ ì§€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë‹¤ì‹œ í•œë²ˆ ë§ì”€ë“œë¦¬ë©´, ì €í¬ì˜ ìë³¸ ìš°ì„ ìˆœìœ„ëŠ” ì²«ì§¸, ì‚¬ì—… ì¬íˆ¬ì, ë‘˜ì§¸, M&A, ì…‹ì§¸, ê¸°íšŒì  ìì‚¬ì£¼ ë§¤ì…ì…ë‹ˆë‹¤.</td></tr>
<tr><td>On that front, we have $103 million remaining on our buyback authorization with no share repurchases year-to-date. Turning to our outlook for 2025. With our strong first half behind us and the high visibility we have to our backlog of repeat sales for the rest of 2025, we are on track for another outstanding year, better than our long-term algorithm of 20% revenue growth with 20% adjusted EBITDA margin. We now expect full year 2025 net revenue will be between $799 million and $804 million, representing around 23% to 24% year-over-year growth. We expect gross margin will be 71%, which includes the full impact of tariffs expected in 2025 based on the information we have today.</td><td>ì´ì™€ ê´€ë ¨í•˜ì—¬, ì €í¬ëŠ” ìì‚¬ì£¼ ë§¤ì… ìŠ¹ì¸í•œë„ì—ì„œ 1ì–µ 300ë§Œ ë‹¬ëŸ¬ê°€ ë‚¨ì•„ìˆìœ¼ë©°, ì—°ì´ˆ ëŒ€ë¹„ ìì‚¬ì£¼ ë§¤ì…ì€ ì—†ì—ˆìŠµë‹ˆë‹¤. 2025ë…„ ì „ë§ìœ¼ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤. ê°•ë ¥í•œ ìƒë°˜ê¸° ì‹¤ì ê³¼ 2025ë…„ ë‚˜ë¨¸ì§€ ê¸°ê°„ ë™ì•ˆì˜ ë°˜ë³µ ë§¤ì¶œ ë°±ë¡œê·¸ì— ëŒ€í•œ ë†’ì€ ê°€ì‹œì„±ì„ ë°”íƒ•ìœ¼ë¡œ, ì €í¬ëŠ” ë§¤ì¶œ ì„±ì¥ë¥  20%, ì¡°ì • EBITDA ë§ˆì§„ 20%ë¼ëŠ” ì¥ê¸° ì•Œê³ ë¦¬ì¦˜ë³´ë‹¤ ìš°ìˆ˜í•œ ë˜ ë‹¤ë¥¸ ë›°ì–´ë‚œ í•œ í•´ë¥¼ ë³´ë‚¼ ê²ƒìœ¼ë¡œ ì˜ˆìƒë©ë‹ˆë‹¤. <br><br>í˜„ì¬ 2025ë…„ ì „ì²´ ìˆœë§¤ì¶œì€ 7ì–µ 9,900ë§Œ ë‹¬ëŸ¬ì—ì„œ 8ì–µ 400ë§Œ ë‹¬ëŸ¬ ì‚¬ì´ë¡œ ì˜ˆìƒí•˜ë©°, ì´ëŠ” ì „ë…„ ëŒ€ë¹„ ì•½ 23%ì—ì„œ 24%ì˜ ì„±ì¥ë¥ ì„ ë‚˜íƒ€ëƒ…ë‹ˆë‹¤. ë§¤ì¶œì´ì´ìµë¥ ì€ 71%ë¡œ ì˜ˆìƒë˜ë©°, ì´ëŠ” í˜„ì¬ ë³´ìœ í•œ ì •ë³´ë¥¼ ë°”íƒ•ìœ¼ë¡œ 2025ë…„ì— ì˜ˆìƒë˜ëŠ” ê´€ì„¸ì˜ ì „ì²´ ì˜í–¥ì„ í¬í•¨í•œ ìˆ˜ì¹˜ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Adjusted EBITDA is expected to be between $160 million and $162 million, and we expect adjusted diluted EPS of between $2.06 and $2.09, assuming no share buybacks in 2025. For Brand 3, we're focused on a successful launch and are on track to hit our Q4 official timing. As a reminder, there is no revenue contribution from Brand 3 baked into our 2025 outlook, and we are not reliant on the brand to achieve our revenue objectives this year or next year for that matter. Turning to 2026. It's too early to issue formal guidance at this stage.</td><td>ì¡°ì • EBITDAëŠ” 1ì–µ 6ì²œë§Œ ë‹¬ëŸ¬ì—ì„œ 1ì–µ 6ì²œ 2ë°±ë§Œ ë‹¬ëŸ¬ ì‚¬ì´ë¡œ ì˜ˆìƒë˜ë©°, 2025ë…„ ìì‚¬ì£¼ ë§¤ì…ì´ ì—†ë‹¤ê³  ê°€ì •í•  ë•Œ ì¡°ì • í¬ì„ ì£¼ë‹¹ìˆœì´ìµì€ 2.06ë‹¬ëŸ¬ì—ì„œ 2.09ë‹¬ëŸ¬ ì‚¬ì´ë¥¼ ì˜ˆìƒí•©ë‹ˆë‹¤. ë¸Œëœë“œ 3ì˜ ê²½ìš°, ì„±ê³µì ì¸ ì¶œì‹œì— ì§‘ì¤‘í•˜ê³  ìˆìœ¼ë©° 4ë¶„ê¸° ê³µì‹ ì¶œì‹œ ì¼ì •ì„ ë§ì¶œ ìˆ˜ ìˆëŠ” ê¶¤ë„ì— ìˆìŠµë‹ˆë‹¤. ì°¸ê³ ë¡œ, ë¸Œëœë“œ 3ìœ¼ë¡œë¶€í„°ì˜ ë§¤ì¶œ ê¸°ì—¬ë¶„ì€ 2025ë…„ ì „ë§ì— ë°˜ì˜ë˜ì–´ ìˆì§€ ì•Šìœ¼ë©°, ì˜¬í•´ë‚˜ ë‚´ë…„ì˜ ë§¤ì¶œ ëª©í‘œ ë‹¬ì„±ì„ ìœ„í•´ í•´ë‹¹ ë¸Œëœë“œì— ì˜ì¡´í•˜ì§€ ì•Šê³  ìˆìŠµë‹ˆë‹¤. 2026ë…„ìœ¼ë¡œ ë„˜ì–´ê°€ì„œ, í˜„ ë‹¨ê³„ì—ì„œëŠ” ê³µì‹ì ì¸ ê°€ì´ë˜ìŠ¤ë¥¼ ì œì‹œí•˜ê¸°ì—ëŠ” ë„ˆë¬´ ì´ë¦…ë‹ˆë‹¤.</td></tr>
<tr><td>But based on what we know today, we expect 2026 financial performance will be in line with our long-term earnings algorithm of 20% revenue growth with a 20% adjusted EBITDA margin. A note for your models, we plan to front load our investments in the first half of 2026, which could equate to a 700 basis point drag on first half EBITDA margin next year, with most of the impact weighted to the first quarter. This planned spending should be offset by a margin benefit from lower relative spending in the second half of the year. All of this results in neutral impact to adjusted EBITDA margin in 2026, which again is expected to land at 20%, consistent with our long-term algorithm.</td><td>í•˜ì§€ë§Œ í˜„ì¬ ìš°ë¦¬ê°€ ì•Œê³  ìˆëŠ” ì •ë³´ë¥¼ ë°”íƒ•ìœ¼ë¡œ, 2026ë…„ ì¬ë¬´ ì„±ê³¼ëŠ” ë§¤ì¶œ ì„±ì¥ë¥  20%, ì¡°ì • EBITDA ë§ˆì§„ 20%ë¼ëŠ” ìš°ë¦¬ì˜ ì¥ê¸° ìˆ˜ìµ ì•Œê³ ë¦¬ì¦˜ê³¼ ì¼ì¹˜í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒë©ë‹ˆë‹¤. ì—¬ëŸ¬ë¶„ì˜ ëª¨ë¸ë§ì„ ìœ„í•´ ì°¸ê³ í•˜ì‹¤ ì ì€, ìš°ë¦¬ê°€ 2026ë…„ ìƒë°˜ê¸°ì— íˆ¬ìë¥¼ ì„ í–‰ì ìœ¼ë¡œ ì§‘í–‰í•  ê³„íšì´ë©°, ì´ëŠ” ë‚´ë…„ ìƒë°˜ê¸° EBITDA ë§ˆì§„ì— 700 ë² ì´ì‹œìŠ¤ í¬ì¸íŠ¸ì˜ ë¶€ë‹´ìœ¼ë¡œ ì‘ìš©í•  ìˆ˜ ìˆë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. ì´ ì˜í–¥ì˜ ëŒ€ë¶€ë¶„ì€ 1ë¶„ê¸°ì— ì§‘ì¤‘ë  ê²ƒì…ë‹ˆë‹¤. ì´ëŸ¬í•œ ê³„íšëœ ì§€ì¶œì€ í•˜ë°˜ê¸° ìƒëŒ€ì  ì§€ì¶œ ê°ì†Œë¡œ ì¸í•œ ë§ˆì§„ ê°œì„  íš¨ê³¼ë¡œ ìƒì‡„ë  ê²ƒì…ë‹ˆë‹¤. ì´ ëª¨ë“  ê²ƒì„ ì¢…í•©í•˜ë©´ 2026ë…„ ì¡°ì • EBITDA ë§ˆì§„ì— ì¤‘ë¦½ì ì¸ ì˜í–¥ì„ ë¯¸ì¹˜ê²Œ ë˜ë©°, ë‹¤ì‹œ í•œë²ˆ ë§ì”€ë“œë¦¬ì§€ë§Œ ìš°ë¦¬ì˜ ì¥ê¸° ì•Œê³ ë¦¬ì¦˜ê³¼ ì¼ì¹˜í•˜ëŠ” 20%ì— ë„ë‹¬í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒë©ë‹ˆë‹¤.</td></tr>
<tr><td>Turning to the third quarter outlook. We're off to a good start with momentum following through from the second quarter. We expect year-over-year net revenue growth in the quarter to be between 21% and 23%. You can find more details on our Q3 outlook in our press release. And with that, I'll turn the call back to the operator for questions.</td><td>3ë¶„ê¸° ì „ë§ìœ¼ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤. 2ë¶„ê¸°ì˜ ëª¨ë©˜í…€ì´ ì´ì–´ì§€ë©´ì„œ ì¢‹ì€ ì¶œë°œì„ ë³´ì´ê³  ìˆìŠµë‹ˆë‹¤. 3ë¶„ê¸° ìˆœë§¤ì¶œ ì „ë…„ ë™ê¸° ëŒ€ë¹„ ì„±ì¥ë¥ ì€ 21%ì—ì„œ 23% ì‚¬ì´ê°€ ë  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•©ë‹ˆë‹¤. 3ë¶„ê¸° ì „ë§ì— ëŒ€í•œ ìì„¸í•œ ë‚´ìš©ì€ ë³´ë„ìë£Œì—ì„œ í™•ì¸í•˜ì‹¤ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì´ì œ ì§ˆì˜ì‘ë‹µì„ ìœ„í•´ ì˜¤í¼ë ˆì´í„°ì—ê²Œ ë‹¤ì‹œ ë„˜ê¸°ê² ìŠµë‹ˆë‹¤.</td></tr>
    </table>
    <h3>ğŸ“Œ ìš”ì•½</h3>
    <p style="background:#f0f0f0; padding:15px; border-left: 5px solid #333;">â€¢ ì‹¤ì  í•˜ì´ë¼ì´íŠ¸:<br>- 2025ë…„ 2ë¶„ê¸° ë§¤ì¶œ 241ë°±ë§Œ ë‹¬ëŸ¬ (ì „ë…„ ëŒ€ë¹„ 25% ì¦ê°€)<br>- ì¡°ì • EBITDA 70ë°±ë§Œ ë‹¬ëŸ¬, ë§ˆì§„ìœ¨ 28.8%<br>- ìƒë°˜ê¸° ê¸°ì¤€ í”„ë¦¬ìºì‹œí”Œë¡œìš° 99ë°±ë§Œ ë‹¬ëŸ¬ (EBITDA ëŒ€ë¹„ 80% ì´ìƒì˜ ì „í™˜ìœ¨)<br><br>â€¢ ì‚¬ì—… í˜„í™©:<br>- IL MAKIAGEì™€ SpoiledChild ëª¨ë‘ ì˜¨ë¼ì¸ ë§¤ì¶œ ë‘ ìë¦¿ìˆ˜ ì„±ì¥<br>- í•´ì™¸ ë§¤ì¶œ ë¹„ì¤‘ 15% (ê²½ìŸì‚¬ 70% ëŒ€ë¹„ ì„±ì¥ ì—¬ë ¥ í¼)<br>- SpoiledChildëŠ” 2025ë…„ 200ë°±ë§Œ ë‹¬ëŸ¬ ë§¤ì¶œ ë‹¬ì„± ì˜ˆìƒ<br><br>â€¢ í–¥í›„ ì „ë§:<br>- 2025ë…„ ì—°ê°„ ë§¤ì¶œ 799-804ë°±ë§Œ ë‹¬ëŸ¬ ì˜ˆìƒ (23-24% ì„±ì¥)<br>- Brand 3(ì˜ë£Œë“±ê¸‰ í™”ì¥í’ˆ) 2025ë…„ 4ë¶„ê¸° ì¶œì‹œ ì˜ˆì •<br>- 2026ë…„ 20% ë§¤ì¶œ ì„±ì¥ê³¼ 20% EBITDA ë§ˆì§„ ëª©í‘œ ìœ ì§€</p>
    <hr style="margin:50px 0;">
    

    <h2>â“ Q&A</h2>
    <table style="width:100%; border-collapse:collapse; margin-bottom: 40px;">
        <tr>
            <th style="width:50%; border-bottom: 2px solid #333;">Original</th>
            <th style="width:50%; border-bottom: 2px solid #333;">Translation</th>
        </tr>
        <tr><td>Operator: [Operator Instructions] Our first question comes from Youssef Squali of Truist Securities.</td><td>**Operator:** [ìš´ì˜ì ì•ˆë‚´] ì²« ë²ˆì§¸ ì§ˆë¬¸ì€ íŠ¸ë£¨ì´ìŠ¤íŠ¸ ì‹œíë¦¬í‹°ì¦ˆì˜ ìœ ì„¸í”„ ìŠ¤ì½¸ë¦¬ë‹˜ê»˜ì„œ ì£¼ì…¨ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Youssef Houssaini Squali: Congrats on a solid quarter. So maybe just at a high level, maybe on the gross margin for Q3, Lindsay, the guide, it came in slightly below consensus expectations. Can you maybe unpack that a little bit? What's driving the sequential compression there? Is it volume, mix, investment associated with Brand 3, et cetera? And just to clarify, in your prepared remarks, I think you just said something to the effect that the 20% -- you believe you can grow 20% next year even without any contribution from Brand 3. Can you just confirm that?</td><td>**Youssef Houssaini Squali:** ê²¬ì‹¤í•œ ë¶„ê¸° ì‹¤ì ì„ ì¶•í•˜ë“œë¦½ë‹ˆë‹¤. ë†’ì€ ìˆ˜ì¤€ì—ì„œ 3ë¶„ê¸° ë§¤ì¶œì´ì´ìµë¥ ì— ëŒ€í•´ ì§ˆë¬¸ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ë¦°ì§€, ê°€ì´ë˜ìŠ¤ê°€ ì»¨ì„¼ì„œìŠ¤ ì˜ˆìƒì¹˜ë¥¼ ì•½ê°„ í•˜íšŒí–ˆëŠ”ë°ìš”. ì´ ë¶€ë¶„ì„ ì¢€ ë” ìì„¸íˆ ì„¤ëª…í•´ ì£¼ì‹¤ ìˆ˜ ìˆë‚˜ìš”? ìˆœì°¨ì  ì••ë°• ìš”ì¸ì´ ë¬´ì—‡ì¸ì§€ìš”? ë¬¼ëŸ‰ì¸ì§€, ë¯¹ìŠ¤ì¸ì§€, ë¸Œëœë“œ 3ê³¼ ê´€ë ¨ëœ íˆ¬ìì¸ì§€ ë“±ë“± ë§ì´ì£ . ê·¸ë¦¬ê³  ëª…í™•íˆ í•˜ìë©´, ì¤€ë¹„ëœ ë°œì–¸ì—ì„œ 20% - ë¸Œëœë“œ 3ì˜ ê¸°ì—¬ ì—†ì´ë„ ë‚´ë…„ì— 20% ì„±ì¥í•  ìˆ˜ ìˆë‹¤ê³  ë¯¿ëŠ”ë‹¤ê³  ë§ì”€í•˜ì‹  ê²ƒ ê°™ì€ë°ìš”. ì´ ë¶€ë¶„ì„ í™•ì¸í•´ ì£¼ì‹¤ ìˆ˜ ìˆë‚˜ìš”?</td></tr>
<tr><td>Lindsay Drucker Mann: Yes. Thanks for the question, Youssef. So on gross margin, as you know, this is not a metric that our teams manage to. They manage to DC margin, which is contribution margin, it's gross margin after media spend. And we have a pretty decent range of gross margin profiles across products that the teams are selling, which they're not managing to. They're only managing to contribution. And as a result, when we issue guidance, we do it in such a way that we give the teams a lot of flexibility to go after whatever it is that makes the right sense from an LTV perspective. We've also, as you know, since you've been covering us since our IPO, we've overdelivered on that metric consistently every quarter as a result of wanting to embed enough conservatism to give the teams flexibility and not be in a position to disappoint the Street. That being said, we do have a little bit of seasonality in our gross margin in the back half of the year. We're much more of a repeat business, as you know, that tends to have a bit more -- a bit lower gross margin profile. And also because the revenue dollars themselves are smaller in Q3 and Q4, we don't get as much leverage on the fixed part of our COGS. So sequentially, you do see a little bit of that in the back half. There's nothing else to make of it. From a business perspective, in Q2, gross margin behavior was flattish year-over-year. We had some puts and takes. We had some higher supply chain expenses that were offset by lower supply chain expenses to end up with a pretty flattish outcome that we were happy with as it exceeded our guidance for the quarter. The next question was on Brand 3 contribution. That's correct. We don't need Brand 3 for our 2025 outlook, and we don't need it for our 2026 outlook. We're obviously doing everything in our control to make sure Brand 3 is an unbelievable success, and we believe that it will be. But we have plenty of growth remaining in both IL MAKIAGE and SpoiledChild. IL MAKIAGE is still on track to achieve $1 billion of revenue in 2028, as Oran mentioned in his remarks. SpoiledChild is having an unbelievable year as well. That will cross $200 million of revenue this year. So we don't need our new brands because we have a lot of growth left in our existing brands. Anything that we deliver is incremental. That being said, our commitment is 20% revenue growth and 20% adjusted EBITDA margin. So if we got more from Brand 3, we wouldn't be changing our guidance.</td><td>**Lindsay Drucker Mann:** ë„¤, ì§ˆë¬¸ ê°ì‚¬í•©ë‹ˆë‹¤. ë§¤ì¶œì´ì´ìµë¥ (gross margin)ì— ëŒ€í•´ì„œ ë§ì”€ë“œë¦¬ë©´, ì•„ì‹œë‹¤ì‹œí”¼ ì´ëŠ” ì €í¬ íŒ€ë“¤ì´ ê´€ë¦¬í•˜ëŠ” ì§€í‘œê°€ ì•„ë‹™ë‹ˆë‹¤. íŒ€ë“¤ì€ DC ë§ˆì§„, ì¦‰ ê¸°ì—¬ì´ìµë¥ (contribution margin)ì„ ê´€ë¦¬í•©ë‹ˆë‹¤. ì´ëŠ” ë¯¸ë””ì–´ ì§€ì¶œì„ ì°¨ê°í•œ í›„ì˜ ë§¤ì¶œì´ì´ìµë¥ ì…ë‹ˆë‹¤. ì €í¬ê°€ íŒë§¤í•˜ëŠ” ì œí’ˆë“¤ ì „ë°˜ì— ê±¸ì³ ë§¤ì¶œì´ì´ìµë¥  í”„ë¡œí•„ì˜ ë²”ìœ„ê°€ ìƒë‹¹íˆ ë„“ì€ë°, íŒ€ë“¤ì€ ì´ë¥¼ ê´€ë¦¬í•˜ì§€ ì•ŠìŠµë‹ˆë‹¤. ì˜¤ì§ ê¸°ì—¬ì´ìµë¥ ë§Œ ê´€ë¦¬í•˜ì£ . <br><br>ê·¸ ê²°ê³¼, ì €í¬ê°€ ê°€ì´ë˜ìŠ¤ë¥¼ ë°œí‘œí•  ë•ŒëŠ” íŒ€ë“¤ì´ LTV(ê³ ê°ìƒì• ê°€ì¹˜) ê´€ì ì—ì„œ ì˜¬ë°”ë¥¸ ì˜ë¯¸ê°€ ìˆëŠ” ê²ƒì´ë¼ë©´ ë¬´ì—‡ì´ë“  ì¶”ì§„í•  ìˆ˜ ìˆë„ë¡ ìƒë‹¹í•œ ìœ ì—°ì„±ì„ ì œê³µí•˜ëŠ” ë°©ì‹ìœ¼ë¡œ ì§„í–‰í•©ë‹ˆë‹¤. ì•„ì‹œë‹¤ì‹œí”¼ IPO ì´í›„ ì €í¬ë¥¼ ê³„ì† ì»¤ë²„í•´ ì˜¤ì…¨ëŠ”ë°, ì €í¬ëŠ” ì´ ì§€í‘œì—ì„œ ë§¤ ë¶„ê¸° ì¼ê´€ë˜ê²Œ ì´ˆê³¼ ë‹¬ì„±í•´ì™”ìŠµë‹ˆë‹¤. íŒ€ë“¤ì—ê²Œ ì¶©ë¶„í•œ ìœ ì—°ì„±ì„ ì œê³µí•˜ê³  ì‹œì¥ì„ ì‹¤ë§ì‹œí‚¤ì§€ ì•Šê¸° ìœ„í•´ ì¶©ë¶„í•œ ë³´ìˆ˜ì„±ì„ ë°˜ì˜í•˜ê³ ì í–ˆê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. <br><br>ê·¸ë ‡ê¸´ í•˜ì§€ë§Œ, í•˜ë°˜ê¸° ë§¤ì¶œì´ì´ìµë¥ ì—ëŠ” ì•½ê°„ì˜ ê³„ì ˆì„±ì´ ìˆìŠµë‹ˆë‹¤. ì•„ì‹œë‹¤ì‹œí”¼ ì €í¬ëŠ” ë°˜ë³µ ë¹„ì¦ˆë‹ˆìŠ¤ ë¹„ì¤‘ì´ í›¨ì”¬ ë†’ì€ë°, ì´ëŠ” ë§¤ì¶œì´ì´ìµë¥ ì´ ë‹¤ì†Œ ë‚®ì€ íŠ¹ì„±ì„ ë³´ì…ë‹ˆë‹¤. ë˜í•œ 3ë¶„ê¸°ì™€ 4ë¶„ê¸° ë§¤ì¶œ ê·œëª¨ ìì²´ê°€ ì‘ê¸° ë•Œë¬¸ì— ë§¤ì¶œì›ê°€ì˜ ê³ ì •ë¹„ ë¶€ë¶„ì—ì„œ ë ˆë²„ë¦¬ì§€ íš¨ê³¼ë¥¼ ë§ì´ ì–»ì§€ ëª»í•©ë‹ˆë‹¤. ë”°ë¼ì„œ í•˜ë°˜ê¸°ì—ëŠ” ìˆœì°¨ì ìœ¼ë¡œ ì´ëŸ° í˜„ìƒì„ ì¡°ê¸ˆ ë³´ê²Œ ë©ë‹ˆë‹¤. ê·¸ ì™¸ì— íŠ¹ë³„íˆ í•´ì„í•  ë¶€ë¶„ì€ ì—†ìŠµë‹ˆë‹¤. ë¹„ì¦ˆë‹ˆìŠ¤ ê´€ì ì—ì„œ ë³´ë©´, 2ë¶„ê¸° ì´ë§ˆì§„(gross margin) í–‰íƒœëŠ” ì „ë…„ ë™ê¸° ëŒ€ë¹„ ê±°ì˜ ë³€í™”ê°€ ì—†ì—ˆìŠµë‹ˆë‹¤. ëª‡ ê°€ì§€ ìƒìŠ¹ ìš”ì¸ê³¼ í•˜ë½ ìš”ì¸ì´ ìˆì—ˆëŠ”ë°ìš”. ê³µê¸‰ë§ ë¹„ìš© ì¦ê°€ ìš”ì¸ì´ ìˆì—ˆì§€ë§Œ ê³µê¸‰ë§ ë¹„ìš© ì ˆê° ìš”ì¸ìœ¼ë¡œ ìƒì‡„ë˜ì–´ ê²°êµ­ ê±°ì˜ ë³€í™” ì—†ëŠ” ê²°ê³¼ë¥¼ ì–»ì—ˆìŠµë‹ˆë‹¤. ì´ëŠ” ë¶„ê¸° ê°€ì´ë˜ìŠ¤ë¥¼ ìƒíšŒí•˜ëŠ” ìˆ˜ì¤€ì´ì–´ì„œ ë§Œì¡±ìŠ¤ëŸ¬ì› ìŠµë‹ˆë‹¤. <br><br>ë‹¤ìŒ ì§ˆë¬¸ì€ ë¸Œëœë“œ 3ì˜ ê¸°ì—¬ë„ì— ê´€í•œ ê²ƒì´ì—ˆëŠ”ë°ìš”. ë§ìŠµë‹ˆë‹¤. 2025ë…„ ì „ë§ì— ë¸Œëœë“œ 3ê°€ í•„ìš”í•˜ì§€ ì•Šê³ , 2026ë…„ ì „ë§ì—ë„ í•„ìš”í•˜ì§€ ì•ŠìŠµë‹ˆë‹¤. ë¬¼ë¡  ë¸Œëœë“œ 3ê°€ ì—„ì²­ë‚œ ì„±ê³µì„ ê±°ë‘˜ ìˆ˜ ìˆë„ë¡ ìš°ë¦¬ê°€ í†µì œí•  ìˆ˜ ìˆëŠ” ëª¨ë“  ê²ƒì„ ë‹¤í•˜ê³  ìˆê³ , ì„±ê³µí•  ê²ƒì´ë¼ê³  ë¯¿ìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ IL MAKIAGEì™€ SpoiledChild ëª¨ë‘ì—ì„œ ì¶©ë¶„í•œ ì„±ì¥ ì—¬ë ¥ì´ ë‚¨ì•„ ìˆìŠµë‹ˆë‹¤. IL MAKIAGEëŠ” ì˜¤ë€ì´ ë°œì–¸ì—ì„œ ì–¸ê¸‰í–ˆë“¯ì´ 2028ë…„ 10ì–µ ë‹¬ëŸ¬ ë§¤ì¶œ ë‹¬ì„± ëª©í‘œë¥¼ ì—¬ì „íˆ ìˆœì¡°ë¡­ê²Œ ì§„í–‰í•˜ê³  ìˆìŠµë‹ˆë‹¤. SpoiledChildë„ ì •ë§ ë†€ë¼ìš´ í•œ í•´ë¥¼ ë³´ë‚´ê³  ìˆìŠµë‹ˆë‹¤. ì˜¬í•´ ë§¤ì¶œì´ 2ì–µ ë‹¬ëŸ¬ë¥¼ ë„˜ì„ ê²ƒì…ë‹ˆë‹¤. ë”°ë¼ì„œ ê¸°ì¡´ ë¸Œëœë“œì—ì„œ ì•„ì§ ì„±ì¥ ì—¬ë ¥ì´ ë§ê¸° ë•Œë¬¸ì— ìƒˆë¡œìš´ ë¸Œëœë“œê°€ ë°˜ë“œì‹œ í•„ìš”í•œ ê²ƒì€ ì•„ë‹™ë‹ˆë‹¤. ìš°ë¦¬ê°€ ì¶œì‹œí•˜ëŠ” ëª¨ë“  ê²ƒì€ ì¶”ê°€ì ì¸ ì„±ê³¼ì…ë‹ˆë‹¤. <br><br>ê·¸ë ‡ê¸´ í•˜ì§€ë§Œ, ìš°ë¦¬ì˜ ì•½ì†ì€ ë§¤ì¶œ 20% ì„±ì¥ê³¼ ì¡°ì • EBITDA ë§ˆì§„ 20%ì…ë‹ˆë‹¤. ë”°ë¼ì„œ Brand 3ì—ì„œ ë” ë§ì€ ì„±ê³¼ë¥¼ ê±°ë‘”ë‹¤ê³  í•´ë„ ê°€ì´ë˜ìŠ¤ë¥¼ ë³€ê²½í•˜ì§€ëŠ” ì•Šì„ ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>Operator: The next question comes from Lauren Lieberman of Barclays.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ ë°”í´ë ˆì´ì¦ˆì˜ ë¡œë Œ ë¦¬ë²„ë§Œìœ¼ë¡œë¶€í„° ë‚˜ì™”ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Lauren Rae Lieberman: Two questions. One was just a follow up, Lindsay, on the end of your answer to that last question that you wouldn't up your guidance or commitments if Brand 3 comes through strongly and will be incremental. Should we take that as to mean that you'll kind of pull back and constrain the growth on IL MAKIAGE and SpoiledChild to try to manage the business in '26 and beyond to something as close to that 20% as possible? Because I know that, to some extent, the way Oran has talked about the business is we want long-term predictable, very strong growth. And some of that is about managing the pace of growth. So I just want to understand how to think about that for '26 and beyond as Brand 3 comes in as incremental. And then the other thing, which is a shorter term, I think previously, you talked about a soft launch for Brand 3 in the third quarter, and now it's just full committed launch in Q4. Is there any soft launch activity in Q3? And if that's a shift in the launch plan, how come?</td><td>**Lauren Rae Lieberman:** ë‘ ê°€ì§€ ì§ˆë¬¸ì´ ìˆìŠµë‹ˆë‹¤. í•˜ë‚˜ëŠ” ë¦°ì§€, ë°©ê¸ˆ ì „ ì§ˆë¬¸ì— ëŒ€í•œ ë‹µë³€ ë§ˆì§€ë§‰ ë¶€ë¶„ì— ëŒ€í•œ í›„ì† ì§ˆë¬¸ì¸ë°ìš”. ë¸Œëœë“œ 3ê°€ ê°•í•˜ê²Œ ì„±ê³¼ë¥¼ ë‚´ê³  ì¦ë¶„ íš¨ê³¼ë¥¼ ê°€ì ¸ì˜¨ë‹¤ í•´ë„ ê°€ì´ë˜ìŠ¤ë‚˜ ì•½ì†ì„ ìƒí–¥ ì¡°ì •í•˜ì§€ ì•Šê² ë‹¤ê³  í•˜ì…¨ëŠ”ë°, ì´ë¥¼ 26ë…„ ì´í›„ ì‚¬ì—…ì„ 20%ì— ìµœëŒ€í•œ ê°€ê¹ê²Œ ê´€ë¦¬í•˜ê¸° ìœ„í•´ IL MAKIAGEì™€ SpoiledChildì˜ ì„±ì¥ì„ ì–´ëŠ ì •ë„ ì–µì œí•˜ê³  ì œì•½í•  ê²ƒì´ë¼ëŠ” ì˜ë¯¸ë¡œ ë°›ì•„ë“¤ì—¬ì•¼ í• ê¹Œìš”? <br><br>ì˜¤ë€ì´ ì‚¬ì—…ì— ëŒ€í•´ ì´ì•¼ê¸°í•´ì˜¨ ë°©ì‹ì„ ë³´ë©´, ì¥ê¸°ì ìœ¼ë¡œ ì˜ˆì¸¡ ê°€ëŠ¥í•˜ê³  ë§¤ìš° ê°•ë ¥í•œ ì„±ì¥ì„ ì›í•œë‹¤ê³  ì•Œê³  ìˆê±°ë“ ìš”. ê·¸ë¦¬ê³  ê·¸ ì¼ë¶€ëŠ” ì„±ì¥ ì†ë„ë¥¼ ê´€ë¦¬í•˜ëŠ” ê²ƒê³¼ ê´€ë ¨ì´ ìˆì£ . ê·¸ë˜ì„œ ë¸Œëœë“œ 3ê°€ ì¦ë¶„ íš¨ê³¼ë¡œ ë“¤ì–´ì˜¤ëŠ” 26ë…„ ì´í›„ ìƒí™©ì„ ì–´ë–»ê²Œ ìƒê°í•´ì•¼ í• ì§€ ì´í•´í•˜ê³  ì‹¶ìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ë‹¤ë¥¸ ë‹¨ê¸°ì ì¸ ì‚¬ì•ˆì¸ë°ìš”, ì´ì „ì— 3ë¶„ê¸°ì— ë¸Œëœë“œ 3ì˜ ì†Œí”„íŠ¸ ëŸ°ì¹­ì— ëŒ€í•´ ë§ì”€í•˜ì…¨ëŠ”ë°, ì§€ê¸ˆì€ 4ë¶„ê¸°ì— ì™„ì „í•œ ì¶œì‹œë¡œ ê³„íšì´ ë°”ë€ ê²ƒ ê°™ìŠµë‹ˆë‹¤. 3ë¶„ê¸°ì— ì†Œí”„íŠ¸ ëŸ°ì¹­ í™œë™ì´ ìˆì„ ì˜ˆì •ì¸ê°€ìš”? ê·¸ë¦¬ê³  ë§Œì•½ ì¶œì‹œ ê³„íšì´ ë³€ê²½ëœ ê²ƒì´ë¼ë©´, ê·¸ ì´ìœ ëŠ” ë¬´ì—‡ì¸ê°€ìš”?</td></tr>
<tr><td>Oran Holtzman: Yes, I'll take it, Lindsay, and then if you have something, please do. First of all, regarding Brand 3 and the reason that we said it's not baked in, it's already baked in 2026 is that even if Brand 3 is as successful as SpoiledChild, by the way, it was the biggest -- the best launch of all time based on our knowledge to D2C, see $25 million, and it's not material. And therefore, we didn't take it into account when building our next year algorithm. But it doesn't mean that we are not bullish. We are very bullish on Brand 3. We are working it for the past almost 4 years. As for soft launch, soft launch for us, it's a lot of trial runs at smaller scale, smaller acquisition spend to drive some traffic for testing. It's a way for us to identify issues that need to be solved and do a lot of [indiscernible]. Therefore, we will start doing some tests in Q3. And official launch is where we begin spending real dollars both on brand and user acquisition. We are planning to make a big push in Q4 and in Q1 next year. So it means more investments, and this is part of the reason that Lindsay was referring to in H1 next year around margins.</td><td>**Oran Holtzman:** ë„¤, ì œê°€ ë‹µë³€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ë¦°ì§€, ì¶”ê°€ë¡œ ë§ì”€í•˜ì‹¤ ê²ƒì´ ìˆìœ¼ì‹œë©´ í•´ì£¼ì„¸ìš”. ë¨¼ì € ë¸Œëœë“œ 3ì— ëŒ€í•´ì„œ, ê·¸ë¦¬ê³  2026ë…„ì— ë°˜ì˜ë˜ì§€ ì•Šì•˜ë‹¤ê³  ë§ì”€ë“œë¦° ì´ìœ ì— ëŒ€í•´ ì„¤ëª…ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ë¸Œëœë“œ 3ê°€ ìŠ¤í¬ì¼ë“œì°¨ì¼ë“œë§Œí¼ ì„±ê³µí•œë‹¤ê³  í•´ë„, ì°¸ê³ ë¡œ ìŠ¤í¬ì¼ë“œì°¨ì¼ë“œëŠ” ìš°ë¦¬ê°€ ì•Œê¸°ë¡œëŠ” D2C ì—­ì‚¬ìƒ ìµœê³ ì˜ ë¡ ì¹­ì´ì—ˆê³  2,500ë§Œ ë‹¬ëŸ¬ë¥¼ ê¸°ë¡í–ˆì§€ë§Œ, ê·¸ê²ƒë„ ì¤‘ìš”í•˜ì§€ ì•ŠìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ë‚´ë…„ ì•Œê³ ë¦¬ì¦˜ì„ êµ¬ì¶•í•  ë•Œ ì´ë¥¼ ê³ ë ¤í•˜ì§€ ì•Šì•˜ìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ì´ê²ƒì´ ìš°ë¦¬ê°€ ë‚™ê´€ì ì´ì§€ ì•Šë‹¤ëŠ” ëœ»ì€ ì•„ë‹™ë‹ˆë‹¤. ë¸Œëœë“œ 3ì— ëŒ€í•´ì„œëŠ” ë§¤ìš° ë‚™ê´€ì ì…ë‹ˆë‹¤. ê±°ì˜ 4ë…„ ë™ì•ˆ ì‘ì—…í•´ì™”ìŠµë‹ˆë‹¤. <br><br>ì†Œí”„íŠ¸ ë¡ ì¹­ì— ê´€í•´ì„œëŠ”, ìš°ë¦¬ì—ê²Œ ì†Œí”„íŠ¸ ë¡ ì¹­ì´ë€ í…ŒìŠ¤íŠ¸ë¥¼ ìœ„í•´ íŠ¸ë˜í”½ì„ ìœ ë„í•˜ê¸° ìœ„í•œ ì†Œê·œëª¨ ê³ ê° í™•ë³´ ì§€ì¶œë¡œ ë” ì‘ì€ ê·œëª¨ì—ì„œ ë§ì€ ì‹œë²” ìš´ì˜ì„ í•˜ëŠ” ê²ƒì…ë‹ˆë‹¤. í•´ê²°í•´ì•¼ í•  ë¬¸ì œë“¤ì„ íŒŒì•…í•˜ê³  ë§ì€ ì‘ì—…ì„ ìˆ˜í–‰í•˜ëŠ” ë°©ë²•ì…ë‹ˆë‹¤. ë”°ë¼ì„œ 3ë¶„ê¸°ë¶€í„° ì¼ë¶€ í…ŒìŠ¤íŠ¸ë¥¼ ì‹œì‘í•  ì˜ˆì •ì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ê³µì‹ ì¶œì‹œëŠ” ë¸Œëœë“œì™€ ì‚¬ìš©ì í™•ë³´ ëª¨ë‘ì— ì‹¤ì§ˆì ì¸ ë¹„ìš©ì„ íˆ¬ì…í•˜ê¸° ì‹œì‘í•˜ëŠ” ì‹œì ì…ë‹ˆë‹¤. 4ë¶„ê¸°ì™€ ë‚´ë…„ 1ë¶„ê¸°ì— ëŒ€ëŒ€ì ì¸ ì¶”ì§„ì„ ê³„íší•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŠ” ë” ë§ì€ íˆ¬ìë¥¼ ì˜ë¯¸í•˜ë©°, ì´ê²ƒì´ Lindsayê°€ ë‚´ë…„ ìƒë°˜ê¸° ë§ˆì§„ê³¼ ê´€ë ¨í•´ì„œ ì–¸ê¸‰í–ˆë˜ ì´ìœ  ì¤‘ í•˜ë‚˜ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Lindsay Drucker Mann: Lauren, just to follow up on the final part of your -- one of your questions was which was about will you constrain? And the answer is that, yes, we constrain all the time. We have the ability to grow faster than the actual numbers that we deliver. And our approach is to make sure that every single year, we can compound at 20% revenue growth with 20% adjusted EBITDA margins for many, many years to come as opposed to pulling any of that growth forward when we don't need it. So the right way to think about your models as you build in the out year is that we will have many, many levers of growth. We'll consistently deliver on that algorithm and that you can feel confident in our ability to sustain that growth and compound in the future.</td><td>**Lindsay Drucker Mann:** ë¡œë Œ, ë§ˆì§€ë§‰ ì§ˆë¬¸ ì¤‘ í•˜ë‚˜ì˜€ë˜ ì„±ì¥ì„ ì œì•½í•  ê²ƒì¸ì§€ì— ëŒ€í•œ í›„ì† ë‹µë³€ì„ ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ë„¤, ì €í¬ëŠ” í•­ìƒ ì œì•½ì„ ê°€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì‹¤ì œ ë°œí‘œí•˜ëŠ” ìˆ˜ì¹˜ë³´ë‹¤ ë” ë¹ ë¥´ê²Œ ì„±ì¥í•  ìˆ˜ ìˆëŠ” ëŠ¥ë ¥ì„ ë³´ìœ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì €í¬ ì ‘ê·¼ë²•ì€ í•„ìš”í•˜ì§€ ì•Šì€ ì„±ì¥ì„ ì•ë‹¹ê¸°ê¸°ë³´ë‹¤ëŠ”, ë§¤ë…„ ìˆ˜ìµ 20% ì„±ì¥ê³¼ ì¡°ì • EBITDA ë§ˆì§„ 20%ë¥¼ í–¥í›„ ìˆ˜ë…„ê°„ ì§€ì†ì ìœ¼ë¡œ ë³µë¦¬ë¡œ ë‹¬ì„±í•  ìˆ˜ ìˆë„ë¡ í•˜ëŠ” ê²ƒì…ë‹ˆë‹¤.<br><br>í–¥í›„ ì—°ë„ ëª¨ë¸ì„ êµ¬ì¶•í•˜ì‹¤ ë•Œ ì˜¬ë°”ë¥¸ ê´€ì ì€ ì €í¬ê°€ ë‹¤ì–‘í•œ ì„±ì¥ ë™ë ¥ì„ ë³´ìœ í•˜ê³  ìˆë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. ì €í¬ëŠ” ì´ëŸ¬í•œ ê³µì‹ì„ ì¼ê´€ë˜ê²Œ ë‹¬ì„±í•  ê²ƒì´ë©°, í–¥í›„ ì´ëŸ¬í•œ ì„±ì¥ì„ ì§€ì†í•˜ê³  ë³µë¦¬ ì„±ì¥ì„ ì´ì–´ê°ˆ ìˆ˜ ìˆëŠ” ì €í¬ ëŠ¥ë ¥ì— ëŒ€í•´ í™•ì‹ ì„ ê°€ì§€ì…”ë„ ë©ë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Our next question comes from Anna Lizzul of Bank of America.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ ë±…í¬ì˜¤ë¸Œì•„ë©”ë¦¬ì¹´ì˜ Anna Lizzulë¡œë¶€í„° ë°›ì•˜ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Anna Jeanne Lizzul: I was wondering if you could just elaborate a bit more on your investment in the business here with the launch of Brand 3 later this year and then Brand 4 next year? And then when do you expect we'll start seeing some returns here on just the investments with those launches?</td><td>**Anna Jeanne Lizzul:** ì˜¬í•´ ë§ ë¸Œëœë“œ 3 ì¶œì‹œì™€ ë‚´ë…„ ë¸Œëœë“œ 4 ì¶œì‹œì™€ ê´€ë ¨ëœ ì‚¬ì—… íˆ¬ìì— ëŒ€í•´ ì¢€ ë” ìì„¸íˆ ì„¤ëª…í•´ ì£¼ì‹¤ ìˆ˜ ìˆì„ê¹Œìš”? ê·¸ë¦¬ê³  ì´ëŸ¬í•œ ì¶œì‹œ íˆ¬ìì— ëŒ€í•œ ìˆ˜ìµì´ ì–¸ì œì¯¤ ë‚˜íƒ€ë‚˜ê¸° ì‹œì‘í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ì‹œëŠ”ì§€ìš”?</td></tr>
<tr><td>Oran Holtzman: Sure. Lindsay, I'll start. We continue to invest a lot of our margin dollars in the future. And going back to the previous question, there is no reason, in my view, to deliver higher margin than 20%, especially when we believe those investments could be massive unlocks for the business performance and for the growth in the future. And when we think about investments, there are mainly 3 pillars. Number one is new brands, Brand 3, Brand 4, each has its own team many years already spending a lot of money and a lot of time on building those brands. Number two is ODDITY Labs, which we continue to build. We have around 70 scientists there in Boston. We continue to invest a lot in infrastructure and building this machine. And lastly, technology, it continues to be the largest team in the company. We acquired a small company this year. We expand the team, and we believe this is the right thing to do. As for like what is the -- what about the future? Like in my point of view, we invested $25 million or $20 million in SpoiledChild, and today, 3 years later, it's $200 million of revenue and very, very healthy margins. So I hope that we'll continue to invest in this space, and we will see the margins and the growth coming.</td><td>**Oran Holtzman:** ë„¤, ì‹œì‘í•˜ê² ìŠµë‹ˆë‹¤. ì €í¬ëŠ” ê³„ì†í•´ì„œ ë§ˆì§„ ìˆ˜ìµì˜ ìƒë‹¹ ë¶€ë¶„ì„ ë¯¸ë˜ì— íˆ¬ìí•˜ê³  ìˆìŠµë‹ˆë‹¤. ì•ì„  ì§ˆë¬¸ê³¼ ì—°ê²°í•´ì„œ ë§ì”€ë“œë¦¬ë©´, ì œê°€ ë³´ê¸°ì—ëŠ” 20%ë³´ë‹¤ ë†’ì€ ë§ˆì§„ì„ ë‹¬ì„±í•  ì´ìœ ê°€ ì—†ìŠµë‹ˆë‹¤. íŠ¹íˆ ì´ëŸ¬í•œ íˆ¬ìë“¤ì´ ë¹„ì¦ˆë‹ˆìŠ¤ ì„±ê³¼ì™€ ë¯¸ë˜ ì„±ì¥ì— ì—„ì²­ë‚œ ì ì¬ë ¥ì„ ì—´ì–´ì¤„ ìˆ˜ ìˆë‹¤ê³  ë¯¿ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤.<br><br>íˆ¬ìì— ëŒ€í•´ ìƒê°í•´ë³´ë©´ ì£¼ë¡œ 3ê°œì˜ ê¸°ë‘¥ì´ ìˆìŠµë‹ˆë‹¤. ì²« ë²ˆì§¸ëŠ” ìƒˆë¡œìš´ ë¸Œëœë“œë“¤ì…ë‹ˆë‹¤. ë¸Œëœë“œ 3, ë¸Œëœë“œ 4ëŠ” ê°ê° ê³ ìœ í•œ íŒ€ì„ ë³´ìœ í•˜ê³  ìˆìœ¼ë©°, ì´ë¯¸ ìˆ˜ë…„ê°„ ì´ëŸ¬í•œ ë¸Œëœë“œ êµ¬ì¶•ì— ë§ì€ ìê¸ˆê³¼ ì‹œê°„ì„ íˆ¬ì…í•´ì™”ìŠµë‹ˆë‹¤. ë‘ ë²ˆì§¸ëŠ” ODDITY Labsì…ë‹ˆë‹¤. ì´ ë¶€ë¬¸ì„ ì§€ì†ì ìœ¼ë¡œ êµ¬ì¶•í•˜ê³  ìˆìœ¼ë©°, ë³´ìŠ¤í„´ì— ì•½ 70ëª…ì˜ ê³¼í•™ìë“¤ì´ ìˆìŠµë‹ˆë‹¤. ì¸í”„ë¼ì™€ ì´ ì‹œìŠ¤í…œ êµ¬ì¶•ì— ê³„ì†í•´ì„œ ë§ì€ íˆ¬ìë¥¼ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë§ˆì§€ë§‰ìœ¼ë¡œ ê¸°ìˆ  ë¶€ë¬¸ì€ ì—¬ì „íˆ íšŒì‚¬ ë‚´ ê°€ì¥ í° íŒ€ì…ë‹ˆë‹¤. ì˜¬í•´ ì†Œê·œëª¨ íšŒì‚¬ë¥¼ ì¸ìˆ˜í–ˆê³  íŒ€ì„ í™•ì¥í–ˆëŠ”ë°, ì´ê²ƒì´ ì˜¬ë°”ë¥¸ ê²°ì •ì´ë¼ê³  ìƒê°í•©ë‹ˆë‹¤. ë¯¸ë˜ì— ëŒ€í•´ì„œëŠ” ì œ ê´€ì ì—ì„œ ë³´ë©´, SpoiledChildì— 2,500ë§Œ ë‹¬ëŸ¬ ë˜ëŠ” 2,000ë§Œ ë‹¬ëŸ¬ë¥¼ íˆ¬ìí–ˆëŠ”ë°, 3ë…„ì´ ì§€ë‚œ ì§€ê¸ˆ 2ì–µ ë‹¬ëŸ¬ì˜ ë§¤ì¶œê³¼ ë§¤ìš° ê±´ì „í•œ ë§ˆì§„ì„ ê¸°ë¡í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì•ìœ¼ë¡œë„ ì´ ë¶„ì•¼ì— ì§€ì†ì ìœ¼ë¡œ íˆ¬ìí•  ê²ƒì´ë©°, ë§ˆì§„ê³¼ ì„±ì¥ì´ ë”°ë¼ì˜¬ ê²ƒìœ¼ë¡œ ê¸°ëŒ€í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Our next question comes from Andrew Boone of Citizens.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ Citizensì˜ Andrew Booneìœ¼ë¡œë¶€í„° ë°›ì•˜ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Andrew M. Boone: I wanted to ask about International and just the drivers of growth going forward there. Can you guys just talk about whether that includes new markets, deeper penetration or anything else we should be thinking about as we think through the international opportunity? And then, Lindsay, I want to go back to just a reoccurring theme of just repeat rates. Is there anything you guys can share either on cohorts, repeat rates to help us better understand how kind of the existing customers are progressing on the platform?</td><td>**Andrew M. Boone:** êµ­ì œ ì‚¬ì—…ê³¼ í–¥í›„ ì„±ì¥ ë™ë ¥ì— ëŒ€í•´ ì§ˆë¬¸ë“œë¦¬ê³  ì‹¶ìŠµë‹ˆë‹¤. ìƒˆë¡œìš´ ì‹œì¥ ì§„ì¶œ, ê¸°ì¡´ ì‹œì¥ì—ì„œì˜ ì¹¨íˆ¬ìœ¨ í™•ëŒ€, ë˜ëŠ” êµ­ì œ ì‚¬ì—… ê¸°íšŒë¥¼ ìƒê°í•  ë•Œ ê³ ë ¤í•´ì•¼ í•  ë‹¤ë¥¸ ìš”ì†Œë“¤ì— ëŒ€í•´ ë§ì”€í•´ ì£¼ì‹¤ ìˆ˜ ìˆë‚˜ìš”? ê·¸ë¦¬ê³  Lindsay, ë°˜ë³µ êµ¬ë§¤ìœ¨ì´ë¼ëŠ” ì§€ì†ì ì¸ ì£¼ì œë¡œ ëŒì•„ê°€ì„œ ì§ˆë¬¸ë“œë¦¬ëŠ”ë°ìš”. ì½”í˜¸íŠ¸ë‚˜ ë°˜ë³µ êµ¬ë§¤ìœ¨ì— ëŒ€í•´ ê³µìœ í•´ ì£¼ì‹¤ ìˆ˜ ìˆëŠ” ë‚´ìš©ì´ ìˆë‚˜ìš”? ê¸°ì¡´ ê³ ê°ë“¤ì´ í”Œë«í¼ì—ì„œ ì–´ë–»ê²Œ ë°œì „í•˜ê³  ìˆëŠ”ì§€ ë” ì˜ ì´í•´í•  ìˆ˜ ìˆë„ë¡ ë„ì›€ì„ ì£¼ì‹œë©´ ì¢‹ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Lindsay Drucker Mann: Sure. I'll take the International piece. International is an area we're super excited about. This is a part of the business we've been, as you guys know, laying the foundation for, for years now, really preparing the markets and getting them ready. And now as of -- we talked to you guys on the Q4 call that we were taking a step forward to move this like even further down the field in terms of executing on those markets. Very happy with our first half performance. This is a business that could easily be as large as our U.S. business. As you know, for our competitors, it's something like 70% of their business comes from international markets. And everything that we see is that the markets behave very similarly outside the U.S. to what we have already accomplished in the U.S. Just to give you -- put a little bit of numbers around it, in the first half, sales outside the U.S. grew over 40%, that's around $85 million. Of that $85 million, $75 million were markets that were already established in. So for example, U.K., Australia. But we have around $10 million from these new kind of testing markets where we see a lot of potential. I say all this just to illustrate how much runway there is. So for emerging markets for us or I should say, prospective markets for us like France, Italy, Spain, where the metrics are really positive. It's nice. The teams have been in preparation mode to finally actually be executing on it. There's still -- we're still very early stages. There's still a lot of runway, but it's been fun to see that take shape this year. And as we look into 2026, we have even more going on. In terms of what that's involved, of course, it's been more spend, more actual user acquisition activity in those markets, ad sets, creative, all that kind of stuff, but it's also been a lot of focus on the teams, physical products...</td><td>**Lindsay Drucker Mann:** ë„¤, í•´ì™¸ ì‚¬ì—… ë¶€ë¶„ì— ëŒ€í•´ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. í•´ì™¸ ì‚¬ì—…ì€ ì €í¬ê°€ ì •ë§ ê¸°ëŒ€í•˜ê³  ìˆëŠ” ì˜ì—­ì…ë‹ˆë‹¤. ì•„ì‹œë‹¤ì‹œí”¼ ì €í¬ê°€ ìˆ˜ë…„ê°„ ê¸°ë°˜ì„ ë‹¤ì ¸ì˜¨ ì‚¬ì—… ë¶€ë¶„ìœ¼ë¡œ, ì‹œì¥ì„ ì¤€ë¹„í•˜ê³  ì •ë¹„í•´ì™”ìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì´ì œ 4ë¶„ê¸° ì‹¤ì  ë°œí‘œì—ì„œ ë§ì”€ë“œë¦° ë°”ì™€ ê°™ì´, í•´ë‹¹ ì‹œì¥ë“¤ì—ì„œì˜ ì‹¤í–‰ë ¥ì„ ë”ìš± ê°•í™”í•˜ê¸° ìœ„í•´ í•œ ë‹¨ê³„ ë” ë‚˜ì•„ê°€ê³  ìˆìŠµë‹ˆë‹¤. ìƒë°˜ê¸° ì„±ê³¼ì— ë§¤ìš° ë§Œì¡±í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ ì‚¬ì—…ì€ ì¶©ë¶„íˆ ë¯¸êµ­ ì‚¬ì—…ë§Œí¼ í° ê·œëª¨ê°€ ë  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì•„ì‹œë‹¤ì‹œí”¼ ê²½ìŸì‚¬ë“¤ì˜ ê²½ìš° ë§¤ì¶œì˜ ì•½ 70%ê°€ í•´ì™¸ ì‹œì¥ì—ì„œ ë‚˜ì˜¤ê³  ìˆìŠµë‹ˆë‹¤. ì €í¬ê°€ ë³´ê¸°ì—ëŠ” ë¯¸êµ­ ì™¸ ì‹œì¥ë“¤ì´ ì €í¬ê°€ ì´ë¯¸ ë¯¸êµ­ì—ì„œ ë‹¬ì„±í•œ ê²ƒê³¼ ë§¤ìš° ìœ ì‚¬í•˜ê²Œ ì‘ë™í•˜ê³  ìˆìŠµë‹ˆë‹¤. êµ¬ì²´ì ì¸ ìˆ˜ì¹˜ë¥¼ ë§ì”€ë“œë¦¬ë©´, ìƒë°˜ê¸°ì— ë¯¸êµ­ ì™¸ ì§€ì—­ ë§¤ì¶œì´ 40% ì´ìƒ ì„±ì¥í•´ì„œ ì•½ 8,500ë§Œ ë‹¬ëŸ¬ë¥¼ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤. ì´ 8,500ë§Œ ë‹¬ëŸ¬ ì¤‘ 7,500ë§Œ ë‹¬ëŸ¬ëŠ” ì´ë¯¸ ì§„ì¶œí•´ ìˆë˜ ì‹œì¥ì—ì„œ ë‚˜ì˜¨ ê²ƒì…ë‹ˆë‹¤. ì˜ˆë¥¼ ë“¤ì–´ ì˜êµ­, í˜¸ì£¼ ê°™ì€ ê³³ì´ì£ . í•˜ì§€ë§Œ ì•½ 1,000ë§Œ ë‹¬ëŸ¬ëŠ” ì ì¬ë ¥ì´ í° ìƒˆë¡œìš´ í…ŒìŠ¤íŠ¸ ì‹œì¥ì—ì„œ ë‚˜ì˜¨ ë§¤ì¶œì…ë‹ˆë‹¤. <br><br>ì´ëŸ° ë§ì”€ì„ ë“œë¦¬ëŠ” ì´ìœ ëŠ” ì–¼ë§ˆë‚˜ ë§ì€ ì„±ì¥ ì—¬ì§€ê°€ ìˆëŠ”ì§€ ë³´ì—¬ë“œë¦¬ê¸° ìœ„í•´ì„œì…ë‹ˆë‹¤. í”„ë‘ìŠ¤, ì´íƒˆë¦¬ì•„, ìŠ¤í˜ì¸ ê°™ì€ ìš°ë¦¬ì—ê²ŒëŠ” ì‹ í¥ ì‹œì¥ì´ë¼ê³  í•  ìˆ˜ ìˆëŠ”, ì•„ë‹ˆ ì •í™•íˆëŠ” ìœ ë§ ì‹œì¥ì´ë¼ê³  í•´ì•¼ê² ë„¤ìš”, ì´ëŸ° ê³³ë“¤ì—ì„œ ì§€í‘œë“¤ì´ ì •ë§ ê¸ì •ì ì…ë‹ˆë‹¤. ì¢‹ì€ í˜„ìƒì´ì£ . íŒ€ë“¤ì´ ì¤€ë¹„ ëª¨ë“œì—ì„œ ë“œë””ì–´ ì‹¤ì œ ì‹¤í–‰ ë‹¨ê³„ë¡œ ë„˜ì–´ê°€ê³  ìˆìŠµë‹ˆë‹¤. <br><br>ë¬¼ë¡  ì•„ì§ ì´ˆê¸° ë‹¨ê³„ì´ê³  ê°ˆ ê¸¸ì´ ë©€ì§€ë§Œ, ì˜¬í•´ ì´ëŸ° ëª¨ìŠµë“¤ì´ êµ¬ì²´í™”ë˜ëŠ” ê²ƒì„ ë³´ëŠ” ê²ƒì´ ì •ë§ ì¦ê²ìŠµë‹ˆë‹¤. 2026ë…„ì„ ë‚´ë‹¤ë³´ë©´ ë”ìš± ë§ì€ ì¼ë“¤ì´ ì§„í–‰ë˜ê³  ìˆìŠµë‹ˆë‹¤. êµ¬ì²´ì ìœ¼ë¡œ ë§ì”€ë“œë¦¬ë©´, ë¬¼ë¡  ë” ë§ì€ ì§€ì¶œê³¼ í•´ë‹¹ ì‹œì¥ì—ì„œì˜ ì‹¤ì œ ì‚¬ìš©ì í™•ë³´ í™œë™, ê´‘ê³  ì„¸íŠ¸, í¬ë¦¬ì—ì´í‹°ë¸Œ ë“±ì´ í¬í•¨ë˜ì–´ ìˆì§€ë§Œ, íŒ€ê³¼ ë¬¼ë¦¬ì  ì œí’ˆì—ë„ ë§ì€ ì§‘ì¤‘ì„ í•˜ê³  ìˆìŠµë‹ˆë‹¤...</td></tr>
<tr><td>Oran Holtzman: Because we don't have users theirs and we still don't have repeat, therefore, it's more costly for us at the beginning.</td><td>**Oran Holtzman:** ì €í¬ëŠ” ì•„ì§ ì‚¬ìš©ì ê¸°ë°˜ì´ ì—†ê³  ì¬êµ¬ë§¤ë„ ì—†ê¸° ë•Œë¬¸ì— ì´ˆê¸°ì—ëŠ” ë¹„ìš©ì´ ë” ë§ì´ ë“¤ ìˆ˜ë°–ì— ì—†ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Lindsay Drucker Mann: Yes. But also focus from the teams, availability of products, technology products funnels, all those things. So putting those in place, generating a really nice return on them and executing on that market. In terms of -- your next question was on repeat, repeat remains very strong for us. Repeat continues to increase as a percentage of the business year-over-year. And as we look at our 12-month repeat cohorts, those remain very strong, over 100% and performing well for both brands.</td><td>**Lindsay Drucker Mann:** ë„¤, ë§ìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ íŒ€ì˜ ì§‘ì¤‘ë„, ì œí’ˆ ê°€ìš©ì„±, ê¸°ìˆ  ì œí’ˆ íŒŒì´í”„ë¼ì¸ ë“± ëª¨ë“  ìš”ì†Œë“¤ì—ë„ ì´ˆì ì„ ë§ì¶”ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ê²ƒë“¤ì„ ì œëŒ€ë¡œ êµ¬ì¶•í•˜ì—¬ ì •ë§ ì¢‹ì€ ìˆ˜ìµë¥ ì„ ì°½ì¶œí•˜ê³  í•´ë‹¹ ì‹œì¥ì—ì„œ ì‹¤í–‰í•´ ë‚˜ê°€ê³  ìˆìŠµë‹ˆë‹¤.<br><br>ë‹¤ìŒ ì§ˆë¬¸ì´ì—ˆë˜ ì¬êµ¬ë§¤ì— ê´€í•´ì„œëŠ”, ì¬êµ¬ë§¤ìœ¨ì´ ì €í¬ì—ê²Œ ì—¬ì „íˆ ë§¤ìš° ê°•ë ¥í•œ ì§€í‘œë¡œ ë‚˜íƒ€ë‚˜ê³  ìˆìŠµë‹ˆë‹¤. ì¬êµ¬ë§¤ëŠ” ì „ë…„ ëŒ€ë¹„ ì‚¬ì—… ë¹„ì¤‘ì—ì„œ ì§€ì†ì ìœ¼ë¡œ ì¦ê°€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  12ê°œì›” ì¬êµ¬ë§¤ ì½”í˜¸íŠ¸ë¥¼ ì‚´í´ë³´ë©´, 100%ë¥¼ ë„˜ëŠ” ë§¤ìš° ê°•ë ¥í•œ ìˆ˜ì¤€ì„ ìœ ì§€í•˜ê³  ìˆìœ¼ë©° ë‘ ë¸Œëœë“œ ëª¨ë‘ì—ì„œ ì¢‹ì€ ì„±ê³¼ë¥¼ ë³´ì´ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Our next question comes from Mark Mahaney of Evercore. Mark Stephen F. Mahaney Okay I just wanted to ask about the Brand 3 go-to-market strategy. I think given the type of offering, it's probably going to require a different go-to-market strategy than what you've had with the first 2 brands. Could you just talk about your ability to execute well against that? How different the planning is? How do you mitigate some of the operational risk involved?</td><td>**Operator:** ë¸Œëœë“œ 3ì˜ ì‹œì¥ ì§„ì¶œ ì „ëµì— ëŒ€í•´ ì§ˆë¬¸ë“œë¦¬ê³  ì‹¶ìŠµë‹ˆë‹¤. ì œê³µí•˜ëŠ” ì„œë¹„ìŠ¤ì˜ íŠ¹ì„±ìƒ ì²˜ìŒ ë‘ ë¸Œëœë“œì™€ëŠ” ë‹¤ë¥¸ ì‹œì¥ ì§„ì¶œ ì „ëµì´ í•„ìš”í•  ê²ƒ ê°™ì€ë°ìš”. ì´ì— ëŒ€í•´ ì˜ ì‹¤í–‰í•  ìˆ˜ ìˆëŠ” ëŠ¥ë ¥ì´ ìˆëŠ”ì§€, ê³„íšì´ ì–¼ë§ˆë‚˜ ë‹¤ë¥¸ì§€, ê·¸ë¦¬ê³  ê´€ë ¨ëœ ìš´ì˜ ë¦¬ìŠ¤í¬ë¥¼ ì–´ë–»ê²Œ ì™„í™”í•  ê³„íšì¸ì§€ ë§ì”€í•´ ì£¼ì‹¤ ìˆ˜ ìˆë‚˜ìš”?</td></tr>
<tr><td>Oran Holtzman: Sure. I'll start. Look, in terms of -- it's still same, still using our user base, still using our technology. But in addition to that, we have our vision technology that we built for the past, I want to say, 2.5 years. And there is nothing that different except the infrastructure itself for the pharmacy and the third party we work with. One thing that I would say about Brand 3 and our distinctive approach there mostly is around personalization. Our team spent almost 2 years developing the critical personalized treatments and developed almost 25 customer cohorts with unique treatment combination based on our testing. It shows material, material improvement in satisfaction. Some numbers are above 50% comparing to what exists in the market. And I think that the combination here is something that most other companies cannot do. It's both like building the product, but also building the tech products. So the combination, that's what brings us to those numbers. So we are very bullish. And in terms of go-to- market, it's pretty much the same.</td><td>**Oran Holtzman:** ë„¤, ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ê¸°ë³¸ì ìœ¼ë¡œëŠ” ë™ì¼í•©ë‹ˆë‹¤. ì—¬ì „íˆ ìš°ë¦¬ì˜ ì‚¬ìš©ì ê¸°ë°˜ì„ í™œìš©í•˜ê³  ìˆê³ , ìš°ë¦¬ì˜ ê¸°ìˆ ì„ ì‚¬ìš©í•˜ê³  ìˆìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ì—¬ê¸°ì— ë”í•´ì„œ ì§€ë‚œ 2ë…„ ë°˜ ë™ì•ˆ êµ¬ì¶•í•´ì˜¨ ë¹„ì „ ê¸°ìˆ ì´ ìˆìŠµë‹ˆë‹¤. ì•½êµ­ê³¼ í˜‘ë ¥í•˜ëŠ” ì œ3ìë¥¼ ìœ„í•œ ì¸í”„ë¼ ìì²´ë¥¼ ì œì™¸í•˜ê³ ëŠ” ë‹¤ë¥¸ ì ì´ ì—†ìŠµë‹ˆë‹¤.<br><br>Brand 3ì™€ ê´€ë ¨í•´ì„œ ìš°ë¦¬ë§Œì˜ ì°¨ë³„í™”ëœ ì ‘ê·¼ë²•ì— ëŒ€í•´ ë§ì”€ë“œë¦¬ìë©´, ì£¼ë¡œ ê°œì¸í™”(personalization)ì— ì¤‘ì ì„ ë‘ê³  ìˆìŠµë‹ˆë‹¤. ìš°ë¦¬ íŒ€ì€ ê±°ì˜ 2ë…„ê°„ í•µì‹¬ì ì¸ ê°œì¸ ë§ì¶¤ ì¹˜ë£Œë²•ì„ ê°œë°œí•˜ëŠ” ë° ì‹œê°„ì„ íˆ¬ìí–ˆê³ , í…ŒìŠ¤íŠ¸ë¥¼ ë°”íƒ•ìœ¼ë¡œ ê³ ìœ í•œ ì¹˜ë£Œ ì¡°í•©ì„ ê°€ì§„ ì•½ 25ê°œì˜ ê³ ê° ì½”í˜¸íŠ¸ë¥¼ ê°œë°œí–ˆìŠµë‹ˆë‹¤. ì´ëŠ” ë§Œì¡±ë„ì—ì„œ ìƒë‹¹í•œ, ì •ë§ ìƒë‹¹í•œ ê°œì„ ì„ ë³´ì—¬ì£¼ê³  ìˆìŠµë‹ˆë‹¤. ì¼ë¶€ ìˆ˜ì¹˜ëŠ” ê¸°ì¡´ ì‹œì¥ ëŒ€ë¹„ 50% ì´ìƒì˜ ê°œì„ ì„ ë‚˜íƒ€ë‚´ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ì¡°í•©ì€ ëŒ€ë¶€ë¶„ì˜ ë‹¤ë¥¸ íšŒì‚¬ë“¤ì´ í•  ìˆ˜ ì—†ëŠ” ê²ƒì´ë¼ê³  ìƒê°í•©ë‹ˆë‹¤. ì œí’ˆì„ êµ¬ì¶•í•˜ëŠ” ê²ƒê³¼ ë™ì‹œì— ê¸°ìˆ  ì œí’ˆë„ êµ¬ì¶•í•˜ëŠ” ê²ƒì´ì£ . ë°”ë¡œ ì´ ì¡°í•©ì´ ìš°ë¦¬ë¥¼ ê·¸ëŸ° ìˆ˜ì¹˜ë¡œ ì´ëŒì–´ì£¼ëŠ” ê²ƒì…ë‹ˆë‹¤. ê·¸ë˜ì„œ ìš°ë¦¬ëŠ” ë§¤ìš° ë‚™ê´€ì ì…ë‹ˆë‹¤. ì‹œì¥ ì§„ì¶œ ì „ëµ ì¸¡ë©´ì—ì„œë„ ê±°ì˜ ë™ì¼í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Our next question comes from Dara Mohsenian of Morgan Stanley.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ ëª¨ê±´ìŠ¤íƒ ë¦¬ì˜ ë‹¤ë¼ ëª¨ì„¼ë‹ˆì•ˆë‹˜ê»˜ì„œ ì£¼ì…¨ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Dara Warren Mohsenian: Just on Brand 3, can you just take a step back and give us an update on exactly what the brand sort of entails longer term from a consumer standpoint? Obviously, there's the product itself. You also mentioned monitoring. How does the professional recommendation fit in also potentially? And just basically, how we think about revenue from Brand 3? Is it essentially mostly the product itself? Or are you thinking there's substantial opportunity around charging for monitoring or other revenue streams just given commercialization potential in the derm area goes well beyond the product potentially unlike traditional beauty products. So just what's your approach there? And how do you think about the long-term revenue streams?</td><td>**Dara Warren Mohsenian:** Brand 3ì— ëŒ€í•´ í•œ ê±¸ìŒ ë¬¼ëŸ¬ì„œì„œ, ì†Œë¹„ì ê´€ì ì—ì„œ ì´ ë¸Œëœë“œê°€ ì¥ê¸°ì ìœ¼ë¡œ ì–´ë–¤ ì˜ë¯¸ë¥¼ ê°–ëŠ”ì§€ ì—…ë°ì´íŠ¸í•´ ì£¼ì‹¤ ìˆ˜ ìˆë‚˜ìš”? ë¶„ëª…íˆ ì œí’ˆ ìì²´ë„ ìˆê³ , ëª¨ë‹ˆí„°ë§ì— ëŒ€í•´ì„œë„ ì–¸ê¸‰í•˜ì…¨ëŠ”ë°ìš”. ì „ë¬¸ê°€ ì¶”ì²œì€ ì–´ë–»ê²Œ ë“¤ì–´ë§ëŠ” ê±´ê°€ìš”? ê·¸ë¦¬ê³  ê¸°ë³¸ì ìœ¼ë¡œ Brand 3ì˜ ë§¤ì¶œì„ ì–´ë–»ê²Œ ìƒê°í•´ì•¼ í• ê¹Œìš”? ë³¸ì§ˆì ìœ¼ë¡œ ëŒ€ë¶€ë¶„ì´ ì œí’ˆ ìì²´ì—ì„œ ë‚˜ì˜¤ëŠ” ê±´ê°€ìš”? ì•„ë‹ˆë©´ ëª¨ë‹ˆí„°ë§ì´ë‚˜ ë‹¤ë¥¸ ìˆ˜ìµì›ì— ëŒ€í•œ ê³¼ê¸ˆì—ì„œ ìƒë‹¹í•œ ê¸°íšŒê°€ ìˆë‹¤ê³  ë³´ì‹œë‚˜ìš”? í”¼ë¶€ê³¼ ì˜ì—­ì—ì„œì˜ ìƒì—…í™” ì ì¬ë ¥ì€ ê¸°ì¡´ ë·°í‹° ì œí’ˆê³¼ ë‹¬ë¦¬ ì œí’ˆ ìì²´ë¥¼ í›¨ì”¬ ë„˜ì–´ì„¤ ìˆ˜ ìˆìœ¼ë‹ˆê¹Œìš”. ê·¸ë˜ì„œ ì´ ë¶€ë¶„ì— ëŒ€í•œ ì ‘ê·¼ ë°©ì‹ì€ ì–´ë–»ê²Œ ë˜ê³ , ì¥ê¸°ì ì¸ ìˆ˜ìµì›ì— ëŒ€í•´ì„œëŠ” ì–´ë–»ê²Œ ìƒê°í•˜ê³  ê³„ì‹ ê°€ìš”?</td></tr>
<tr><td>Oran Holtzman: Sure. So as I mentioned on the call before, Brand 3 is a telehealth platform with medical-grade products. We are starting with dermatology, but we have already plans for the next categories because we already have the infrastructure of shipping OTC and Rx products for the first time. This is a huge opportunity for ODDITY. And in my view, we are addressing it differently than anyone else. We developed, as I mentioned before, ODDITY most customized and comprehensive line that we did so far. And in addition to that, it's the first time that we are doing something that deep in a new area of OTC and Rx, all to be sold online under our own brand and most products are formulated with existing ingredients. But for the first time, we are going to launch products coming from ODDITY Labs, new molecules. So this is another area where we are very excited about. What else we did here that is different, we were building a mobile app to ensure that compliance is high. Based on our study and our research, one of the main problems in this category is compliance. So we need someone there to coach and to make sure that she is on track for cure. If it means that we need to change her regimen, we will do it automatically, everything with vision technology and doctor setup. And number three is leveraging our 60 million users. As Lindsay mentioned on her part, huge part of our user base is already suffering from those problems. And therefore, we are planning to leverage it and to offer them the product. Don't forget, we use them as design partners to build this line. So we are pretty confident that this is something that is going to be excited also for them.</td><td>**Oran Holtzman:** ì•ì„œ ì–¸ê¸‰í–ˆë“¯ì´ Brand 3ëŠ” ì˜ë£Œê¸‰ ì œí’ˆì„ ë‹¤ë£¨ëŠ” ì›ê²©ì˜ë£Œ í”Œë«í¼ì…ë‹ˆë‹¤. í”¼ë¶€ê³¼ë¡œ ì‹œì‘í•˜ì§€ë§Œ ì´ë¯¸ ë‹¤ìŒ ì¹´í…Œê³ ë¦¬ì— ëŒ€í•œ ê³„íšë„ ê°€ì§€ê³  ìˆìŠµë‹ˆë‹¤. ì™œëƒí•˜ë©´ ì²˜ìŒìœ¼ë¡œ ì¼ë°˜ì˜ì•½í’ˆ(OTC)ê³¼ ì „ë¬¸ì˜ì•½í’ˆ(Rx) ì œí’ˆì„ ë°°ì†¡í•  ìˆ˜ ìˆëŠ” ì¸í”„ë¼ë¥¼ ì´ë¯¸ êµ¬ì¶•í–ˆê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ì´ëŠ” ODDITYì—ê²Œ ì—„ì²­ë‚œ ê¸°íšŒì…ë‹ˆë‹¤. <br><br>ì œê°€ ë³´ê¸°ì—ëŠ” ë‹¤ë¥¸ ëˆ„êµ¬ì™€ë„ ë‹¤ë¥¸ ë°©ì‹ìœ¼ë¡œ ì´ ì‹œì¥ì— ì ‘ê·¼í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì•ì„œ ë§ì”€ë“œë¦° ë°”ì™€ ê°™ì´ ì§€ê¸ˆê¹Œì§€ ìš°ë¦¬ê°€ ë§Œë“  ê²ƒ ì¤‘ ê°€ì¥ ë§ì¶¤í™”ë˜ê³  í¬ê´„ì ì¸ ë¼ì¸ì„ ê°œë°œí–ˆìŠµë‹ˆë‹¤. ê²Œë‹¤ê°€ OTCì™€ Rxë¼ëŠ” ìƒˆë¡œìš´ ì˜ì—­ì—ì„œ ì´ë ‡ê²Œ ê¹Šì´ ìˆê²Œ ì§„í–‰í•˜ëŠ” ê²ƒì€ ì²˜ìŒì…ë‹ˆë‹¤. ëª¨ë“  ì œí’ˆì€ ìì‚¬ ë¸Œëœë“œë¡œ ì˜¨ë¼ì¸ì—ì„œ íŒë§¤ë  ì˜ˆì •ì´ë©°, ëŒ€ë¶€ë¶„ì˜ ì œí’ˆì€ ê¸°ì¡´ ì„±ë¶„ìœ¼ë¡œ ì œì¡°ë©ë‹ˆë‹¤. í•˜ì§€ë§Œ ì´ë²ˆì—ëŠ” ì²˜ìŒìœ¼ë¡œ ODDITY Labsì—ì„œ ê°œë°œí•œ ì‹ ë¶„ì ì œí’ˆë“¤ì„ ì¶œì‹œí•  ì˜ˆì •ì…ë‹ˆë‹¤. ì´ ë¶€ë¶„ì—ì„œ ì €í¬ëŠ” ë§¤ìš° ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤. <br><br>ì—¬ê¸°ì„œ ì €í¬ê°€ ë‹¤ë¥´ê²Œ ì ‘ê·¼í•œ ë˜ ë‹¤ë¥¸ ì ì€ ì»´í”Œë¼ì´ì–¸ìŠ¤ë¥¼ ë†’ì´ê¸° ìœ„í•´ ëª¨ë°”ì¼ ì•±ì„ êµ¬ì¶•í–ˆë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. ì €í¬ ì—°êµ¬ ê²°ê³¼ì— ë”°ë¥´ë©´, ì´ ì¹´í…Œê³ ë¦¬ì˜ ì£¼ìš” ë¬¸ì œ ì¤‘ í•˜ë‚˜ê°€ ë°”ë¡œ ì»´í”Œë¼ì´ì–¸ìŠ¤ì…ë‹ˆë‹¤. ê·¸ë˜ì„œ ê³ ê°ì„ ì½”ì¹­í•˜ê³  ì¹˜ë£Œ ê³¼ì •ì—ì„œ ì œëŒ€ë¡œ ì§„í–‰ë˜ê³  ìˆëŠ”ì§€ í™•ì¸í•  ìˆ˜ ìˆëŠ” ì‹œìŠ¤í…œì´ í•„ìš”í•©ë‹ˆë‹¤. ë§Œì•½ ê³ ê°ì˜ ì¹˜ë£Œë²•ì„ ë³€ê²½í•´ì•¼ í•œë‹¤ë©´, ë¹„ì „ ê¸°ìˆ ê³¼ ì˜ì‚¬ ì„¤ì •ì„ í†µí•´ ëª¨ë“  ê²ƒì„ ìë™ìœ¼ë¡œ ì²˜ë¦¬í•  ê²ƒì…ë‹ˆë‹¤.<br><br>ì„¸ ë²ˆì§¸ëŠ” ì €í¬ì˜ 6ì²œë§Œ ì‚¬ìš©ìë¥¼ í™œìš©í•˜ëŠ” ê²ƒì…ë‹ˆë‹¤. ë¦°ì§€ê°€ ì•ì„œ ì–¸ê¸‰í–ˆë“¯ì´, ì €í¬ ì‚¬ìš©ì ê¸°ë°˜ì˜ ìƒë‹¹ ë¶€ë¶„ì´ ì´ë¯¸ ì´ëŸ° ë¬¸ì œë“¤ë¡œ ê³ ìƒí•˜ê³  ìˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ì €í¬ëŠ” ì´ë¥¼ í™œìš©í•´ì„œ ê·¸ë“¤ì—ê²Œ ì œí’ˆì„ ì œê³µí•  ê³„íšì…ë‹ˆë‹¤. ì €í¬ê°€ ì´ ì œí’ˆ ë¼ì¸ì„ êµ¬ì¶•í•  ë•Œ ê·¸ë“¤ì„ ë””ìì¸ íŒŒíŠ¸ë„ˆë¡œ í™œìš©í–ˆë‹¤ëŠ” ì ì„ ìŠì§€ ë§ˆì„¸ìš”. ê·¸ë˜ì„œ ì´ê²ƒì´ ê·¸ë“¤ì—ê²Œë„ í¥ë¯¸ë¡œìš´ ì œí’ˆì´ ë  ê²ƒì´ë¼ê³  ìƒë‹¹íˆ í™•ì‹ í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Dara Warren Mohsenian: Great. That's helpful. And you mentioned some of the metrics which have you excited in your testing for Brand 3. Just take us back versus where you were 3 months ago? And what have you learned in the last 3 months in that testing? Has that changed how you're thinking about the commercial process going forward or excited.</td><td>**Dara Warren Mohsenian:** í›Œë¥­í•©ë‹ˆë‹¤. ë„ì›€ì´ ë˜ì—ˆìŠµë‹ˆë‹¤. ë¸Œëœë“œ 3 í…ŒìŠ¤íŒ…ì—ì„œ ê¸°ëŒ€í•˜ê²Œ ë§Œë“œëŠ” ëª‡ ê°€ì§€ ì§€í‘œë“¤ì„ ì–¸ê¸‰í•´ ì£¼ì…¨ëŠ”ë°ìš”. 3ê°œì›” ì „ê³¼ ë¹„êµí•´ì„œ ì–´ë–¤ ìƒí™©ì¸ì§€ ë§ì”€í•´ ì£¼ì‹œê² ìŠµë‹ˆê¹Œ? ì§€ë‚œ 3ê°œì›”ê°„ì˜ í…ŒìŠ¤íŒ…ì—ì„œ ë¬´ì—‡ì„ ë°°ìš°ì…¨ë‚˜ìš”? ê·¸ê²ƒì´ í–¥í›„ ìƒì—…í™” í”„ë¡œì„¸ìŠ¤ì— ëŒ€í•œ ìƒê°ì„ ë°”ê¾¸ê²Œ í–ˆê±°ë‚˜ ë”ìš± ê¸°ëŒ€í•˜ê²Œ ë§Œë“¤ì—ˆë‚˜ìš”?</td></tr>
<tr><td>Oran Holtzman: Yes, 3 months is a short cycle. It takes us like 3 months to get a read, okay? But I can tell you that comparing to 2 years ago, comparing to a year ago, we are in a better position substantially. And I think that the key here was to unlock both, first of all, the diagnosis and in addition to that, to make sure that we are shipping the right customized product. So even if we had the right product or the right molecule a year ago or 2 years ago, if we ship -- if we send it to the wrong tester, therefore, the satisfaction was low. And I think that we made a big progress in matching the right patient with the right treatment.</td><td>**Oran Holtzman:** ë„¤, 3ê°œì›”ì€ ì§§ì€ ì£¼ê¸°ì…ë‹ˆë‹¤. ì €í¬ê°€ ê²°ê³¼ë¥¼ íŒŒì•…í•˜ëŠ” ë° ì•½ 3ê°œì›” ì •ë„ ê±¸ë¦¬ê±°ë“ ìš”. í•˜ì§€ë§Œ 2ë…„ ì „ê³¼ ë¹„êµí•´ì„œ, 1ë…„ ì „ê³¼ ë¹„êµí•´ì„œ ì €í¬ëŠ” ìƒë‹¹íˆ ë‚˜ì€ ìœ„ì¹˜ì— ìˆë‹¤ê³  ë§ì”€ë“œë¦´ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì—¬ê¸°ì„œ í•µì‹¬ì€ ë‘ ê°€ì§€ë¥¼ ëª¨ë‘ í•´ê²°í•˜ëŠ” ê²ƒì´ì—ˆìŠµë‹ˆë‹¤. ìš°ì„  ì§„ë‹¨ ë¶€ë¶„ì„ í•´ê²°í•˜ê³ , ì¶”ê°€ë¡œ ì˜¬ë°”ë¥¸ ë§ì¶¤í˜• ì œí’ˆì„ ë°°ì†¡í•˜ëŠ” ê²ƒì„ í™•ì‹¤íˆ í•˜ëŠ” ê²ƒì´ì—ˆì£ .<br><br>1ë…„ ì „ì´ë‚˜ 2ë…„ ì „ì— ì˜¬ë°”ë¥¸ ì œí’ˆì´ë‚˜ ì˜¬ë°”ë¥¸ ë¶„ìë¥¼ ê°€ì§€ê³  ìˆì—ˆë‹¤ê³  í•´ë„, ì˜ëª»ëœ ê²€ì‚¬ìì—ê²Œ ë³´ë‚¸ë‹¤ë©´ ë§Œì¡±ë„ê°€ ë‚®ì„ ìˆ˜ë°–ì— ì—†ì—ˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì €í¬ëŠ” ì˜¬ë°”ë¥¸ í™˜ìì™€ ì˜¬ë°”ë¥¸ ì¹˜ë£Œë²•ì„ ë§¤ì¹­í•˜ëŠ” ë¶€ë¶„ì—ì„œ í° ì§„ì „ì„ ì´ë¤˜ë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Our next question comes from Scott Schoenhaus of KeyBanc Capital Markets.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ KeyBanc Capital Marketsì˜ Scott Schoenhausë‹˜ê»˜ì„œ ì£¼ì…¨ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Scott Anthony Schoenhaus: Oran, as a health care technology analyst, I think this Brand 3 launch is a really exciting expansion opportunity. Everyone knows in health care dermatology providers are supply constrained and waiting for an appointment can take months to a year. I guess it seems like the launch is centered around -- initially around acne and offering topical treatments and prescriptions that are showing better efficacy than tretinoin currently. But I guess maybe talk about the opportunities with more acute conditions. I think you mentioned eczema. This could be an entirely different platform, bringing in a whole new customer set and people coming to your platform with really severe skin conditions. So kind of just walk me through the trajectory of how you view Brand 3 and the opportunities there as you emerge as a health care technology company.</td><td>**Scott Anthony Schoenhaus:** í—¬ìŠ¤ì¼€ì–´ ê¸°ìˆ  ë¶„ì„ê°€ë¡œì„œ, ì´ë²ˆ Brand 3 ì¶œì‹œëŠ” ì •ë§ í¥ë¯¸ì§„ì§„í•œ í™•ì¥ ê¸°íšŒë¼ê³  ìƒê°í•©ë‹ˆë‹¤. í—¬ìŠ¤ì¼€ì–´ ë¶„ì•¼ì—ì„œ í”¼ë¶€ê³¼ ì˜ë£Œì§„ë“¤ì´ ê³µê¸‰ ë¶€ì¡± ìƒí™©ì— ìˆê³  ì§„ë£Œ ì˜ˆì•½ì„ ì¡ìœ¼ë ¤ë©´ ëª‡ ë‹¬ì—ì„œ 1ë…„ê¹Œì§€ ê¸°ë‹¤ë ¤ì•¼ í•œë‹¤ëŠ” ê²ƒì€ ëª¨ë‘ê°€ ì•Œê³  ìˆëŠ” ì‚¬ì‹¤ì…ë‹ˆë‹¤. ì´ë²ˆ ì¶œì‹œê°€ ì´ˆê¸°ì—ëŠ” ì—¬ë“œë¦„ì„ ì¤‘ì‹¬ìœ¼ë¡œ í•˜ì—¬ í˜„ì¬ íŠ¸ë ˆí‹°ë…¸ì¸ë³´ë‹¤ ë” ë‚˜ì€ íš¨ëŠ¥ì„ ë³´ì´ëŠ” êµ­ì†Œ ì¹˜ë£Œì œì™€ ì²˜ë°©ì•½ì„ ì œê³µí•˜ëŠ” ê²ƒìœ¼ë¡œ ë³´ì…ë‹ˆë‹¤. í•˜ì§€ë§Œ ë” ê¸‰ì„±ì¸ ì§ˆí™˜ë“¤ì— ëŒ€í•œ ê¸°íšŒì— ëŒ€í•´ ë§ì”€í•´ ì£¼ì‹¤ ìˆ˜ ìˆì„ê¹Œìš”? ìŠµì§„ì— ëŒ€í•´ì„œë„ ì–¸ê¸‰í•˜ì‹  ê²ƒ ê°™ì€ë°ìš”. ì´ëŠ” ì™„ì „íˆ ë‹¤ë¥¸ í”Œë«í¼ì´ ë  ìˆ˜ ìˆê³ , ì •ë§ ì‹¬ê°í•œ í”¼ë¶€ ì§ˆí™˜ì„ ê°€ì§„ ì‚¬ëŒë“¤ê³¼ ì™„ì „íˆ ìƒˆë¡œìš´ ê³ ê°ì¸µì„ í”Œë«í¼ìœ¼ë¡œ ëŒì–´ë“¤ì¼ ìˆ˜ ìˆì„ ê²ƒ ê°™ìŠµë‹ˆë‹¤. Brand 3ì˜ ê¶¤ì ê³¼ í—¬ìŠ¤ì¼€ì–´ ê¸°ìˆ  ê¸°ì—…ìœ¼ë¡œ ë¶€ìƒí•˜ë©´ì„œ ê·¸ê³³ì—ì„œ ë³´ê³  ìˆëŠ” ê¸°íšŒë“¤ì— ëŒ€í•´ ì„¤ëª…í•´ ì£¼ì‹œê² ìŠµë‹ˆê¹Œ?</td></tr>
<tr><td>Oran Holtzman: Sure. Thank you for that. And I'm happy that you agree with us, and that's the reason why we launched it, to be honest, because it's such a headache and with very low satisfaction. We start -- the main focus for the beginning of the launch will be around acne and hyperpigmentation. Those are 2 areas that we believe that we have a very strong breakthrough around both the technology and the offering itself. We are ready also with eczema. I think that we're going to have great products out there, but it's a smaller -- like smaller prevalence, and therefore, the main push will be around acne and pigmentation at the beginning. We are going to launch also other body products in Q1 next year. And in addition to that, we are working on additional categories. As for your question, yes, new users -- it's something that we are happy about because it's going to diverse our user base. But you may be surprised, but many of our user base today is suffering from those problems. And this is why we started with like solving it. We saw at least 20%, 25% in each problem that we are about to launch, and we said that -- and we start to ask questions what is wrong there. And they answered us. And in this way, we built this line. And I think that, that's a very good start for launching the brand.</td><td>**Oran Holtzman:** ë„¤, ê°ì‚¬í•©ë‹ˆë‹¤. ì €í¬ì™€ ê°™ì€ ìƒê°ì„ í•´ì£¼ì…”ì„œ ê¸°ì©ë‹ˆë‹¤. ì†”ì§íˆ ë§ì”€ë“œë¦¬ë©´, ë°”ë¡œ ê·¸ëŸ° ì´ìœ  ë•Œë¬¸ì— ì €í¬ê°€ ì´ ì œí’ˆì„ ì¶œì‹œí•˜ê²Œ ëœ ê²ƒì…ë‹ˆë‹¤. ì •ë§ ê³¨ì¹˜ ì•„í”ˆ ë¬¸ì œì´ë©´ì„œ ë§Œì¡±ë„ëŠ” ë§¤ìš° ë‚®ê±°ë“ ìš”.<br><br>ì¶œì‹œ ì´ˆê¸°ì—ëŠ” ì—¬ë“œë¦„ê³¼ ìƒ‰ì†Œì¹¨ì°©ì— ì£¼ë ¥í•  ì˜ˆì •ì…ë‹ˆë‹¤. ì´ ë‘ ì˜ì—­ì—ì„œ ê¸°ìˆ ê³¼ ì œí’ˆ ìì²´ ëª¨ë‘ì—ì„œ ë§¤ìš° ê°•ë ¥í•œ í˜ì‹ ì„ ì´ë¤„ëƒˆë‹¤ê³  í™•ì‹ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ìŠµì§„ ì œí’ˆë„ ì¤€ë¹„ê°€ ì™„ë£Œë˜ì—ˆìŠµë‹ˆë‹¤. í›Œë¥­í•œ ì œí’ˆë“¤ì´ ë‚˜ì˜¬ ê²ƒì´ë¼ê³  ìƒê°í•˜ì§€ë§Œ, ìœ ë³‘ë¥ ì´ ìƒëŒ€ì ìœ¼ë¡œ ë‚®ê¸° ë•Œë¬¸ì— ì´ˆê¸°ì—ëŠ” ì—¬ë“œë¦„ê³¼ ìƒ‰ì†Œì¹¨ì°©ì— ì§‘ì¤‘í•  ê³„íšì…ë‹ˆë‹¤.<br><br>ë‚´ë…„ 1ë¶„ê¸°ì—ëŠ” ë‹¤ë¥¸ ë°”ë”” ì œí’ˆë“¤ë„ ì¶œì‹œí•  ì˜ˆì •ì´ê³ , ê·¸ ì™¸ì—ë„ ì¶”ê°€ ì¹´í…Œê³ ë¦¬ë“¤ì„ ê°œë°œí•˜ê³  ìˆìŠµë‹ˆë‹¤. ë„¤, ì‹ ê·œ ì‚¬ìš©ìì— ëŒ€í•œ ì§ˆë¬¸ì— ë‹µë³€ë“œë¦¬ë©´, ë§ìŠµë‹ˆë‹¤. ì‹ ê·œ ì‚¬ìš©ì í™•ë³´ëŠ” ì €í¬ ì‚¬ìš©ì ê¸°ë°˜ì„ ë‹¤ì–‘í™”í•  ìˆ˜ ìˆì–´ì„œ ë§¤ìš° ê¸°ì˜ê²Œ ìƒê°í•˜ê³  ìˆìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ë†€ë¼ì‹¤ ìˆ˜ë„ ìˆê² ì§€ë§Œ, í˜„ì¬ ì €í¬ ì‚¬ìš©ì ê¸°ë°˜ì˜ ìƒë‹¹ìˆ˜ê°€ ì‹¤ì œë¡œ ì´ëŸ° ë¬¸ì œë“¤ë¡œ ê³ ìƒí•˜ê³  ìˆìŠµë‹ˆë‹¤. <br><br>ê·¸ë˜ì„œ ì €í¬ê°€ ì´ ë¬¸ì œ í•´ê²°ì— ì°©ìˆ˜í•˜ê²Œ ëœ ê²ƒì…ë‹ˆë‹¤. ì €í¬ê°€ ì¶œì‹œí•˜ë ¤ëŠ” ê° ë¬¸ì œ ì˜ì—­ì—ì„œ ìµœì†Œ 20%, 25%ì˜ ì‚¬ìš©ìë“¤ì´ í•´ë‹¹ ë¬¸ì œë¥¼ ê²ªê³  ìˆë‹¤ëŠ” ê²ƒì„ í™•ì¸í–ˆìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ ì €í¬ê°€ "ì—¬ê¸°ì„œ ë­ê°€ ì˜ëª»ëœ ê±´ì§€" ì§ˆë¬¸ì„ ë˜ì§€ê¸° ì‹œì‘í–ˆê³ , ì‚¬ìš©ìë“¤ì´ ë‹µë³€í•´ ì£¼ì—ˆìŠµë‹ˆë‹¤. ì´ëŸ° ë°©ì‹ìœ¼ë¡œ ì´ ì œí’ˆ ë¼ì¸ì„ êµ¬ì¶•í•˜ê²Œ ë˜ì—ˆìŠµë‹ˆë‹¤. <br><br>ë¸Œëœë“œ ì¶œì‹œë¥¼ ìœ„í•œ ë§¤ìš° ì¢‹ì€ ì¶œë°œì ì´ë¼ê³  ìƒê°í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Thank you so much. There are no further questions at this time. I would now like to turn the call back over to Oran Holtzman for his closing remarks. Oran? Thank you.</td><td>**Operator:** ê°ì‚¬í•©ë‹ˆë‹¤. í˜„ì¬ ë” ì´ìƒ ì§ˆë¬¸ì´ ì—†ìŠµë‹ˆë‹¤. ì´ì œ ë§ˆë¬´ë¦¬ ë°œì–¸ì„ ìœ„í•´ ì˜¤ë€ í™€ì¸ ë§Œì—ê²Œ ë‹¤ì‹œ ì—°ê²°í•´ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ì˜¤ë€? ê°ì‚¬í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Oran Holtzman: Thank you very much. See you next quarter.</td><td>**Oran Holtzman:** ê°ì‚¬í•©ë‹ˆë‹¤. ë‹¤ìŒ ë¶„ê¸°ì— ëµ™ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Ladies and gentlemen, this concludes today's conference call. Thank you for your participation. You may now disconnect.</td><td>**Operator:** ì—¬ëŸ¬ë¶„, ì˜¤ëŠ˜ ì»¨í¼ëŸ°ìŠ¤ ì½œì„ ë§ˆì¹˜ê² ìŠµë‹ˆë‹¤. ì°¸ì—¬í•´ ì£¼ì…”ì„œ ê°ì‚¬í•©ë‹ˆë‹¤. ì´ì œ ì—°ê²°ì„ ì¢…ë£Œí•˜ì…”ë„ ë©ë‹ˆë‹¤.</td></tr>
    </table>
    <h3>ğŸ“Œ ìš”ì•½</h3>
    <p style="background:#f0f0f0; padding:15px; border-left: 5px solid #333;">â€¢ ì‹¤ì  í•˜ì´ë¼ì´íŠ¸:<br>- Q2 ì‹¤ì  ì–‘í˜¸, ë§¤ì¶œ ë° ì´ìµ ê°€ì´ë˜ìŠ¤ ìƒíšŒ<br>- êµ­ì œ ì‚¬ì—… ë§¤ì¶œ 40% ì„±ì¥ (ìƒë°˜ê¸° 8,500ë§Œ ë‹¬ëŸ¬)<br>- SpoiledChild ë¸Œëœë“œ ì—°ê°„ 2ì–µ ë‹¬ëŸ¬ ë§¤ì¶œ ë‹¬ì„± ì˜ˆìƒ<br><br>â€¢ ì‹ ê·œ ë¸Œëœë“œ ì „ëµ:<br>- Brand 3ëŠ” 2023ë…„ Q4 ì •ì‹ ì¶œì‹œ ì˜ˆì •, í”¼ë¶€ê³¼ ì›ê²©ì§„ë£Œ í”Œë«í¼ <br>- ê¸°ì¡´ ë¸Œëœë“œë§Œìœ¼ë¡œë„ 2025-26ë…„ 20% ì„±ì¥ ëª©í‘œ ë‹¬ì„± ê°€ëŠ¥<br>- Brand 3 ì„±ê³µ ì‹œ ì¶”ê°€ ì„±ì¥ ë™ë ¥ì´ ë  ê²ƒìœ¼ë¡œ ê¸°ëŒ€<br><br>â€¢ ë¦¬ìŠ¤í¬/ê¸°íšŒ ìš”ì¸:<br>- í•˜ë°˜ê¸° ê³„ì ˆì„±ìœ¼ë¡œ ì¸í•œ ë§¤ì¶œ ê°ì†Œ ë° ë§ˆì§„ ì••ë°• ì˜ˆìƒ<br>- êµ­ì œ ì‹œì¥ í™•ì¥ì— ë”°ë¥¸ ì´ˆê¸° ë¹„ìš© ì¦ê°€<br>- R&D ë° ì‹ ê·œ ë¸Œëœë“œ ê°œë°œ íˆ¬ì ì§€ì† ê³„íš</p>
    <hr style="margin:50px 0;">
    
</body></html>